




(86) Date de dépôt PCT/PCT Filing Date: 2001/10/25	(51) Cl.Int. ⁷ /Int.Cl. ⁷ A61K 48/00, A61K 31/7088, A61P 25/16, A61P 7/06, A61P 1/04, A61P 29/00, C07K 14/705, C07K 14/72, C07K 14/71
(87) Date publication PCT/PCT Publication Date: 2002/08/01	(71) Demandeur/Applicant: NEW ENGLAND MEDICAL CENTER HOSPITALS, INC., US
(85) Entrée phase nationale/National Entry: 2003/04/02	(72) Inventeurs/Inventors: KOPIN, ALAN S., US; BEINBORN, MARTIN, US
(86) N° demande PCT/PCT Application No.: US 2001/050395	(74) Agent: SMART & BIGGAR
(87) N° publication PCT/PCT Publication No.: 2002/059346	
(30) Priorité/Priority: 2000/10/26 (60/243,550) US	

(54) Titre : RECEPTEURS CONSTITUTIVEMENT ACTIFS, HYPERSENSIBLES ET NON FONCTIONNELS UTILISES
COMME NOUVEAUX AGENTS THERAPEUTIQUES
(54) Title: CONSTITUTIVELY ACTIVE, HYPERSENSITIVE, AND NONFUNCTIONAL RECEPTORS AS NOVEL
THERAPEUTIC AGENTS

(57) **Abrégé/Abstract:**

The invention features nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors as novel therapeutic agents. The invention also features a method of treating a mammal, preventing a disease or disorder, or improve health by administering nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors.



(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
1 August 2002 (01.08.2002)

PCT

(10) International Publication Number
WO 02/059346 A2

(51) International Patent Classification⁷: **C12Q**
(21) International Application Number: PCT/US01/50395
(22) International Filing Date: 25 October 2001 (25.10.2001)
(25) Filing Language: English
(26) Publication Language: English
(30) Priority Data:
60/243,550 26 October 2000 (26.10.2000) US
(71) Applicant: **NEW ENGLAND MEDICAL CENTER HOSPITALS, INC.** [US/US]; 750 Washington Street, Boston, MA 02111 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:
— *without international search report and to be republished upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors: **KOPIN, Alan, S.**; 15 Wynnewood Road, Wellesley, MA 02141 (US). **BEINBORN, Martin**; 26 Abbottsford Road, Brookline, MA 02146 (US).
(74) Agent: **ELBING, Karen, L.**; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).

(54) Title: CONSTITUTIVELY ACTIVE, HYPERSENSITIVE, AND NONFUNCTIONAL RECEPTORS AS NOVEL THERAPEUTIC AGENTS

(57) Abstract: The invention features nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors as novel therapeutic agents. The invention also features a method of treating a mammal, preventing a disease or disorder, or improve health by administering nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors.



WO 02/059346 A2

5 CONSTITUTIVELY ACTIVE, HYPERSENSITIVE, AND NONFUNCTIONAL
 RECEPTORS AS NOVEL THERAPEUTIC AGENTS

Statement as to Federally Sponsored Research

 This application was supported in part by NIH grant DK46767. The
government may have certain rights to this invention.

10

Background of the Invention

 In general, this invention relates to the use of nucleic acids encoding
constitutively active, hypersensitive, or nonfunctional receptors in novel therapeutic
compositions and methods.

15

 A major focus of current scientific research is the identification of novel
therapeutic agents that bind endogenous receptors(e.g., G protein-coupled receptors,
single transmembrane receptors, and nuclear receptors). Particularly desirable agents
are agonists and antagonists that activate or block endogenous receptors, respectively, to
provide therapeutic benefit. However, such agonist or antagonist drug therapies may be
20 difficult to find and often carry the risk of severe or undesirable side effects. An
alternative to the use of agonist drug therapy is provided by the present invention in the
form of nucleic acids encoding therapeutically effective constitutively active or
hypersensitive receptors. Additionally, an alternative to the use of antagonist drug
therapy is provided by the present invention in the form of nucleic acids encoding
25 nonfunctional receptors.

Summary of the Invention

 The present invention provides methods of treating or preventing a wide
range of disorders by administering to a mammal a nucleic acid encoding a receptor

having altered activity. These methods may be used to treat a disorder, prevent a disorder, or improve the health of a mammal. Such nucleic acids may encode receptors that are constitutively active, hypersensitive, or nonfunctional. According to the invention, such constitutively active, hypersensitive, or nonfunctional receptors may be

5 G protein-coupled receptors, single transmembrane receptors, or nuclear receptors (for example, steroid hormone receptors).

One particularly preferred constitutively active receptor, which is also a hypersensitive receptor, is a mu opioid receptor. In one example, this receptor is constitutively active as a result of a single point mutation in transmembrane domain 3,

10 preferably, an Asn to Ala point mutation at position 150 of the rat mu opioid receptor of SEQ ID NO: 1, or the human equivalent. Nucleic acids encoding constitutively active mu opioid receptors are useful therapeutic agents for the treatment of pain (for example, back pain) by administration of the nucleic acid, for example, to the intrathecal space of the spinal column. Such administration may block the sensory signal for pain en route

15 to the brain so that pain at any particular location in the body is not perceived by the individual being treated.

Other preferred constitutively active receptors for administering to a mammal include constitutively active dopamine receptors, for example, dopamine 1 or dopamine 2 receptors. These receptors may be administered alone, in combination with one

20 another, and/or in combination with other therapeutics, for the treatment of Parkinson's disease. Preferably, administration is to the brain (for example, to the striatum).

Nucleic acids encoding hypersensitive receptors may also be administered as therapeutic agents according to the invention. In addition to the mu opioid receptor described above, a hypersensitive erythropoietin receptor may also be utilized. This

25 hypersensitive erythropoietin receptor may be used to treat or prevent anemia.

Alternatively, nonfunctional receptors may be administered therapeutically. For example, a nonfunctional CCK-BR receptor may be administered to treat or prevent peptic ulcer disease.

For any of the above methods, expression of the receptor may be accomplished using any promoter or vector system. If desired, receptors may be expressed under the control of an inducible, constitutive, or tissue specific promoter. Viral as well as non-viral vectors may be utilized, with retroviral, adenoviral, and adeno-associated viral vectors being preferred. Viral or nonviral vectors may include cell specific ligands that target administration to a specific cell type in the mammal.

Another integral feature of the present invention is the provision of therapeutic compositions including any of the nucleic acids described herein, such as any nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor (preferably, a constitutively active, hypersensitive, or nonfunctional receptor that is a G protein-coupled receptor, a single transmembrane receptor, or a nuclear receptor) admixed with a pharmaceutically acceptable carrier. One skilled in the art will appreciate that the therapeutic composition is preferably administered at a unit dose sufficient to reduce or eliminate the symptoms of a disease or disorder in a mammal, and such a dose can be easily determined by one of ordinary skill in the art.

The present invention further provides kits containing the nucleic acids and/or therapeutic compositions of the present invention for administration to an individual, for example, an individual diagnosed with a disease or a disorder. The kits may include all reagents required for facile administration by any known route to a patient suffering from a disease or disorder of which the symptoms may be reduced by expression *in vivo* of a receptor having altered activity. Such individuals may be individuals that have been identified as carriers of a particular polymorphism in a

receptor that is linked to the occurrence of a disease, or individuals that may simply be suffering from an acute condition of which the symptoms may be reduced by the inventive approach. The nucleic acids are preferably in containers that also include a pharmaceutically acceptable carrier.

5 In yet another aspect, the gene therapeutic methods, compositions, and kits of the present invention may be used to improve the existing state of health of an individual, for example, by lengthening the individual's life span, improving the individual's physiology, improving the individual's cosmetic appearance, preventing aging (or the appearance of aging) of the individual, increasing the individual's strength,
10 improving the individual's memory, or improving athletic ability of the individual etc. Additional health improving uses will be apparent to those skilled in the art.

By a "constitutively active receptor" is meant a receptor with a higher basal activity level than the corresponding wild-type receptor or a receptor possessing the ability to spontaneously signal in the absence of activation by a positive agonist. This
15 term includes wild-type receptors that are naturally constitutively active (e.g., naturally occurring receptors, including naturally occurring polymorphic receptors and wild-type receptors) and that have a higher basal activity level than a corresponding vector lacking a gene encoding a receptor. The term also includes receptors having mutations (for example, point mutations), as well as receptor chimeras and fusion proteins. In addition,
20 a receptor may be made constitutively active by co-expression with a second protein (such as a homer protein) that regulates receptor activity. The constitutive activity of a receptor may be established by comparing the basal level of signaling, such as second messenger signaling, of a mutant receptor to the basal level of signaling of the wild-type receptor. A constitutively active receptor exhibits at least a 5% increase in basal
25 activity, preferably, at least a 25% increase in basal activity, more preferably at least a

50% increase in basal level activity. It is common for a constitutively active receptor, e.g., a polymorphic constitutively active receptor that is associated with a disease phenotype, to display a relatively small increase in constitutive activity. Preferably, the basal activity of a constitutively active receptor can be confirmed by its decrease in the
5 presence of an inverse agonist.

“Basal” activity means the level of activity (e.g., activation of a specific biochemical pathway or second messenger signaling event) of a receptor in the absence of stimulation with a receptor-specific ligand (e.g., a positive agonist). Preferably, the basal activity is less than the level of ligand-stimulated activity of a wild-type receptor.
10 However, in certain cases, a mutant receptor with increased basal activity might display a level of signaling that approximates, is equal to, or even exceeds the level of ligand-stimulated activity of the corresponding wild-type receptor.

By a “hypersensitive receptor” is meant a receptor having the ability to amplify the input of an endogenous ligand (e.g., a positive or negative agonist), as
15 compared to the wild-type receptor. Such receptors deliver an increased receptor-induced signal in response to a ligand compared to a corresponding wild-type receptor. Hypersensitive receptors may include mutations (for example, point mutations), or may be constructed, for example, as receptor chimeras or fusion proteins. A hypersensitive receptor exhibits at least a 5% increase, preferably, at least a 25% increase, and more
20 preferably at least a 50% increase in ligand-stimulated activity as compared to a corresponding wild-type receptor.

By a “nonfunctional” receptor is meant a receptor that has decreased signaling in response to ligand binding. A nonfunctional receptor may also be a receptor that has reduced binding to a ligand and thus may transmit a weakened signal in
25 response to ligand stimulation. However, ligand binding may not necessarily occur in

every type of nonfunctional receptor. The nonfunctional receptor may be a receptor that is deficient in ligand binding. According to the invention, any mutation that reduces or eliminates ligand-stimulated signaling of a receptor qualifies as a nonfunctional receptor. For example, a nonfunctional receptor could be a receptor that does not bind ligand, and
5 therefore does not transmit a signal in response to ligand binding. A nonfunctional receptor exhibits at least a 5% decrease in ligand-stimulated signal transduction, preferably, at least a 25% decrease in ligand-stimulated signal transduction, and more preferably, at least a 50% reduction in ligand-stimulated signal transduction. Receptors having a decrease in receptor signaling, but not a complete loss of receptor signaling,
10 may be referred to as “hyposensitive receptors.” Such a hyposensitive receptor may have the characteristics of a partial antagonist in the cell and therefore be used in place of partial antagonistic drug therapy treatments. Nonfunctional or hyposensitive receptors may include mutations (for example, point mutations). These receptors may also be constructed as chimeric receptors or fusion proteins.

15 A “naturally-occurring” receptor refers to a form or sequence of a receptor as it exists in an animal, or to a form of the receptor that is homologous to the sequence known to those skilled in the art as the “wild-type” sequence. Those skilled in the art will understand “wild type” receptor to refer to the conventionally accepted “wild-type” amino acid consensus sequence of the receptor, or to a “naturally-occurring” receptor
20 with normal physiological patterns of ligand binding and signaling.

A “mutant receptor” is understood to be a form of the receptor in which one or more amino acid residues in the predominant receptor occurring in nature, e.g., a naturally-occurring wild-type receptor, have been either deleted or replaced. Alternatively additional amino acid residues have been inserted.

25

By "mu opioid receptor" is meant a polypeptide having the analgesic characteristics of the mu opioid receptor, or other associated mu opioid receptor biological activities. These activities include, for example, high affinities for analgesic and addicting opiate drugs (e.g., morphine and fentanyl) and opioid peptides (e.g.,
5 enkephalins, endorphins, and dynorphins (Rothman et al., *Synapse* 21:60-64 (1995); Wang et al., *Proc. Natl. Acad. Sci. USA* 90:10230-10234 (1993); Li et al., *J. Mol. Evol.* 43:179-184 (1996)). In particular examples, the mu opioid receptor has nanomolar affinities for morphine and the enkephalin analog DADLE and clear recognition of naloxonazine (Wang et al., *supra*; Wolozin et al., *Proc. Natl. Acad. Sci. USA* 78:6181-
10 6185 (1981); Eppier et al., *J. Biol. Chem.* 268(35):26447-26451; Golstein et al., *Mol. Pharmacol.* 36:265-272 (1989)). Ligand binding initiates coupling of the mu opioid receptor to adenylate cyclase, causing a decrease in adenylate cyclase activity and a corresponding decrease in the level of intracellular cAMP (Wang et al., *supra*).

By "substantially pure nucleic acid" is meant nucleic acid (e.g., DNA or
15 RNA) that is free of the genes, which, in the naturally-occurring genome of the organism from which the DNA of the invention is derived, flank the gene. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or which exists as a separate molecule (e.g., a cDNA or a genomic or cDNA
20 fragment produced by PCR or restriction endonuclease digestion) independent of other sequences. It also includes a recombinant DNA, which is part of a hybrid gene encoding additional polypeptide sequence.

"Transformed cell" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding
25 (as used herein) a polypeptide described herein (for example, a mu opioid receptor

polypeptide).

"Promoter" means a minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible expression by external signals or agents; such elements may be located in the 5' or 3' regions of the native gene. A promoter element may be positioned for expression if it is positioned adjacent to a DNA sequence so it can direct transcription of the sequence.

"Operably linked" means that a gene and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

"Reporter assay system" means any combination of vectors typically used for measuring transcriptional activation. A typical reporter assay system includes at least a reporter construct and an expression vector encoding the polypeptide that activates (e.g., directly) or causes to activate (e.g., indirectly) expression of the reporter construct. The reporter assay system may also include additional expression vectors encoding other polypeptides that participate in activation of the reporter construct.

"Expression vectors" contain at least a promoter operably linked to the gene to be expressed.

A "reporter construct" includes at least a promoter operably linked to a reporter gene. Such reporter genes may be detected directly (e.g., by visual inspection) or indirectly (e.g., by binding of an antibody to the reporter gene product or by reporter product-mediated induction of a second gene product). Examples of standard reporter genes include genes encoding the luciferase, green fluorescent protein, or chloramphenicol acetyl transferase gene polypeptides (see, for example, Sambrook, J. et

al., *Molecular Cloning: a Laboratory Manual*, Cold Spring Harbor Press, N.Y., or Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, New York, N.Y., V 1-3, 2000, incorporated herein by reference). Expression of the reporter gene is detectable by use of an assay that directly or indirectly measures the activity of the polypeptide encoded by the reporter gene. Preferred reporter constructs also include a response element.

A “response element” is a nucleic acid sequence that is sensitive to a particular signaling pathway, e.g., a second messenger signaling pathway, and assists in driving transcription of the reporter gene in cooperation with the promoter. As used herein, “response element” may also refer to a promoter that is activated in response to signaling through a particular receptor.

By “disease” or “disorder” is meant any ailment or adverse condition that can be diagnosed in a mammal. As used herein, disease or disorder can be used to refer to a physical symptom such as a pain or an ache (e.g., chronic back pain or arthritis etc.) or to refer to a severe condition, such as cancer.

“Disease-inhibiting amount” or “disorder-inhibiting amount” means an amount of nucleic acid that, when delivered to a cell, tissue, or site *in vivo* or *ex vivo*, is capable of reducing, delaying, or stabilizing the symptoms or progression of a disease or disorder with which a patient has been diagnosed. For example, one particularly preferred disease or disorder to be treated by the invention is pain, particularly back pain. According to one preferred embodiment of the invention, an amount of nucleic acid, or a “pain inhibiting amount” of nucleic acid, is preferably delivered to the intrathecal space sufficient to reduce pain at that site.

By “improvement of health” is meant a change of the normal (average) state of health to a state of health that is superior to the normal state of health (e.g., increased strength, prevention of aging, improved memory, or improved athletic ability).

As used herein, “second messenger signaling activity” refers to production of an intracellular stimulus (including, but not limited to, cAMP, cGMP, ppGpp, inositol phosphate, calcium ion) in response to activation of the receptor, or to activation of a protein in response to receptor activation, including but not limited to a kinase, a phosphatase, adenylate cyclase, or phospholipase C, or to activation or inhibition of a membrane channel.

10

Brief Description of the Drawing

Fig. 1 is a table of constitutively active Class A G protein-coupled receptors (SEQ ID NOS: 2-70). The mutations that impart constitutive activity to the receptors are indicated.

15

Fig. 2 is a graph showing the constitutive activity of a D146M MC-4 receptor mutant as assayed by measuring basal level cAMP production.

Fig. 3 is a graph showing the constitutive activity of the L325E CCK-BR receptor as assayed using a luciferase reporter assay.

Fig. 4 is a graph showing the constitutive activity of the Asn150Ala rat mu opioid receptor as assayed using a luciferase reporter assay. This is evidenced by the following: (1) agonist (DAMGO) stimulation of the receptor leads to a decrease in forskolin induced activity, indicating that the receptor works through an inhibiting pathway; (2) forskolin induced activity in the absence of DAMGO is lower with coexpression of mutant receptor (vs. wild-type receptor), indicating ligand independent activity of the inhibitory pathway.

25

Fig. 5 is a graph showing the effects of forskolin stimulation on HEK293 cells transfected with pcDNA1 and a CRE-Luc reporter construct.

Fig. 6 is a graph showing the sensitivity of the reporter constructs, SMS-luc, SRE-Luc, and SRE-Luc + Gq5i to ligand-mediated activation of the mu opioid receptor.

5 Fig. 7 is a graph showing the constitutive activity of the Asn150Ala rat mu opioid receptor as assayed using the SRE-Luc/Gq5i luciferase reporter assay.

Fig. 8 is an illustration of a seven transmembrane domain Class A G protein-coupled receptor. (Selected residues are indicated.)

Fig. 9 is an illustration showing the highly conserved "N" residue among the
10 mu opioid receptor, the bradykinin B2 receptor, and the angiotensin II AT1A receptor. In each of these receptors, mutation of the "N" residue leads to constitutive activity.

Fig. 10 is an illustration showing the "DRY" motif, which is highly conserved among the oxytocin, vasopressin-V2, cholecystokinin-A, melanocortin-4, and 1b adrenergic receptors. In addition, mutation of this "DRY" motif in these receptors
15 leads to constitutive activity.

Fig. 11 is a graph showing the constitutive activity of the D146M MC-4 receptor as assayed using a luciferase reporter assay.

Fig. 12 is an illustration showing the -13 and -20 positions relative to the "CWLP motif." Mutation in the -13 position in the 1A adrenergic receptor, the α 2C
20 adrenergic receptor, the β 2 adrenergic receptor, the serotonin 2A receptor, the cholecystokinin-B receptor, the platelet activating factor receptor, and the thyroid stimulating hormone receptor leads to constitutive activity.

Fig. 13 is an illustration showing a sequence alignment of the human kappa opioid receptor (ork), the rat kappa opioid receptor (orkr), the human mu opioid receptor
25 (orm), the rat mu opioid receptor (ormr), the human delta opioid receptor (ord), the rat

type 1A angiotensin II receptor (AT1A), and the human bradykinin receptor (B2) (SEQ ID NOS: 71-77). Also shown is the N residue, which is located 14 amino acids to the amino-terminus of the "DRY" motif (-14).

Fig. 14 is an illustration showing the amino acid sequence (top to bottom) of the mouse mu opioid receptor, the rat mu opioid receptor, the bovine mu opioid receptor, the human mu opioid receptor, the pig mu opioid receptor, the white sucker (ws) opioid receptor, the angiotensin AT-1 receptor, and the bradykinin-B2 receptor. The N position is highlighted (-14 from the DRY motif). Mutation of this residue leads to constitutive activity in each of these receptors.

Fig. 15 is a graph showing the hypersensitivity of the Asn150Ala rat mutant mu opioid receptor (●), which is also constitutively active, compared to the wild-type mu opioid receptor (▽). Ligand (Damo) was titrated onto the cells expressing either the mutant or the wild-type mu opioid receptor and the luciferase activity was measured to assess the sensitivity of the receptor to ligand stimulation.

Fig. 16 is a graph showing that mutation of the Val at position 331 of the CCK-BR gastrin receptor to a Glu dramatically reduces ligand-stimulated activation of the receptor. CCK-BR activity was determined by measuring ligand induced inositol phosphate production. The illustration to the left of the graph shows the seven membrane spanning topology of the CCK-BR receptor. The larger shaded circle shows amino acid 331.

Fig. 17 is a map of a shuttle vector for adenovirus (pACCMV.pLpA).

Description of the Preferred Embodiments

The present invention is based on the recognition that nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors can be used as

therapeutic agents. According to the present invention, constitutively active, hypersensitive, or nonfunctional receptors include constitutively active, hypersensitive, or nonfunctional G protein-coupled receptors (e.g., opiate receptors), single transmembrane domain receptors (e.g., the erythropoietin receptor (EPOR)), nuclear
5 receptors (e.g., steroid hormone receptors, such as the estrogen receptor), and soluble receptors (Appendices A-E are lists of known receptors that classify as G protein-coupled receptors, single transmembrane domain receptors, and nuclear receptors). In certain preferred embodiments, the invention provides methods of identifying nucleic acids encoding constitutively active, hypersensitive, and nonfunctional receptors. In yet
10 other preferred embodiments, the invention provides a method of treating or preventing a disease in a mammal by administering to the mammal a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor. Alternatively, a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor provides a means of improving the physiology or existing state of health of a mammal (e.g.,
15 increase life span, cosmetic appearance, prevent aging, increase strength, improve memory, improve athletic ability, etc). For example, a constitutively active or hypersensitive erythropoietin receptor has been shown to improve the physiology of a person such that the person has outstanding athletic ability, e.g., improved stamina (Watowich et al., *Blood* 94(7):2530-2532 (1999); Yoshimura et al., *Oncologist*
20 1(5):337-339 (1996)).

Those skilled in the art will appreciate that many aspects of the invention that apply to constitutively active receptors also apply to hypersensitive and nonfunctional receptors. For example, one skilled in the art will recognize that many of the assays described herein may be used to measure constitutive basal activity or ligand-stimulated
25 hypersensitive activity. Alternatively, the skilled artisan will appreciate that any assay

typically used to measure a ligand-stimulated receptor response can be used to detect the absence of that response in a non-functional receptor. In addition, any of the gene therapy methods provided herein may be applied to nucleic acids encoding either constitutively active, hypersensitive, or non-functional receptors.

5 A key feature of the present invention is that it provides a valuable alternative to the administration of agonist and antagonist drugs for the treatment of disease. In contrast to agonist drug therapy, which enhances the activity of endogenous receptors, the present invention provides a recombinant constitutively active receptor that delivers a constitutive intracellular signal that is frequently less than or equivalent to, or perhaps
10 greater than, the signal generated by the agonist drug. Similarly, a recombinant hypersensitive receptor may be used to deliver an enhanced ligand-stimulated signal intracellularly. In addition, in contrast to antagonist drug therapy, which reduces or inhibits the activity of endogenous receptors, the present invention provides recombinant non functional receptors that act as a sink for the endogenous ligand, yet do not
15 transduce a ligand-stimulated signal. Unlike conventional agonist drug therapy, the inventive treatment may be generally both safe and effective, e.g., may induce an intracellular signal sufficient to mimic agonist or antagonist without any side effects.

With respect to the constitutively active receptors, without being bound to any particular theory, the increased basal level activity of the constitutively active
20 receptor is likely due to increased ligand-independent receptor signaling. For example, the expressed receptor may assemble intracellularly and constitutively activate a specific second messenger signaling pathway. Any therapeutic benefit achieved by constitutive second messenger signaling through a recombinant constitutively active receptor provides a number of advantages over systemic administration of agonist drugs,
25 including the elimination of the need for a strict, daily administration regime. For

example, the benefit of obtaining a steady state level of signaling, without having to compensate for the normal metabolic half life of an agonist, is inherent within the system. It is important to appreciate that, according to the present invention, even low level constitutive activity can have beneficial therapeutic effects.

5 With respect to the hypersensitive receptors, we propose, without limitation, that the increased sensitivity to ligand stimulation of a hypersensitive receptor is likely due to an increased affinity of the ligand for the receptor. This increased affinity is then reflected in an increased potency of the receptor upon ligand binding (i.e., the signal generated by ligand binding is amplified compared to the wild-type level of signaling).

10 Similarly, with respect to the nonfunctional receptors, without limiting the mechanism of the invention, it is likely that the inhibition of a signal that is contributing to disease or reduced health, results in a reduction in disease symptoms or improvement in health. For example, the administration of a nonfunctional receptor, i.e., a dominant negative mutant of the receptor, may bind the ligand for the receptor but lack the
15 signaling function of the receptor. This would effectively reduce the extracellular concentration of the ligand for the receptor, while eliminating the signal generated by the particular receptor that is contributing to disease or reduced health.

 According to the present invention, constitutively active receptors include naturally occurring constitutively active receptors and non-naturally occurring (i.e.,
20 mutant) constitutively active receptors. The present invention provides methods of identifying both naturally and non-naturally occurring constitutively active receptors. According to the present invention, constitutively active receptors with increased basal activity are compared to the appropriate negative control. For example, naturally occurring constitutively active receptors can be identified by exhibiting an increased
25 basal level of signaling compared to the activity of a vector lacking a gene encoding a

receptor. Alternatively, mutant receptors having constitutive activity can be identified by comparing the basal level of signaling of the mutant constitutively active receptor to the basal level of signaling of the wild-type receptor. An increase (e.g., by at least 5%) in basal level activity in a candidate receptor compared to a control or wild-type receptor identifies a constitutively active receptor.

Many naturally occurring and non-naturally occurring constitutively active receptors have been previously identified and are available in the art. As described herein, this information can be harnessed and used as a tool to identify additional constitutively active receptors. According to the present invention, the amino acid and/or nucleic acid sequences of known constitutively active receptors are assembled into a database, which is used to identify conserved domains that are important for constitutive activity or mutations within those domains that impart constitutive activity onto the receptor. The sequences of constitutively active polypeptides (mutant and wild-types) in such a database are then compared to the sequence of a given non-constitutively active receptor, and conserved domains are identified between the nonconstitutively active receptor and the constitutively active receptors. This information is further used to identify specific residues within a given nonconstitutively active (e.g., wild-type) receptor that are likely to impart constitutive activity to the nonconstitutively active receptor upon mutation.

Once specific positions in a given nonconstitutively active receptor are targeted for mutation, receptors containing the identified mutations are generated using routine methods and screened for increased constitutive activity (see, for example, Sambrook, J. et al., *Molecular Cloning: a Laboratory Manual*, Cold Spring Harbor Press, N.Y., or Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, New York, N.Y., V 1&3, 2000, incorporated herein by

reference). Preferably, an increase in basal level activity is detected by measuring an increase in basal level signaling in the mutant receptor, compared to the wild-type receptor. The skilled artisan will appreciate that any assay typically used for measuring the ligand-stimulated activity of the wild-type receptor may also be used to measure the
5 basal level activity of a mutant receptor. Such assays are discussed in further detail herein, below.

These general principles can be easily applied by one of ordinary skill in the art to identify hypersensitive receptors or nonfunctional receptors. Hyper-sensitive receptors are receptors that deliver an increased receptor induced signal in response to a
10 ligand, compared to the wild-type receptor. In preferred embodiments, non-naturally occurring receptors that are hypersensitive are identified by comparing the ligand-induced activity of the wild-type receptor to the ligand-induced activity of the mutant receptor; a hypersensitive receptor being identified by its ability to display a stronger signal to a given concentration of ligand than the wild-type receptor. For example, if 5
15 μ M ligand induces a 5-fold stimulation of activity in a wild-type receptor, compared to a negative control, 5 μ M ligand may stimulate a 10-fold stimulation in activity in a hypersensitive receptor, compared to the same negative control. Indeed, hypersensitive mutants of the EPO receptor and the mu opioid receptor have already been identified (Watowich et al., *Blood* 94(7):2530-2532 (1999), incorporated herein by reference).
20 Specifically, mutations in the EPOR that result in familial erythrocytosis result from premature termination of the receptor cytoplasmic region. EPOR mutants lacking the cytoplasmic tail region do not undergo tyrosine phosphorylation, allowing JAK2 activation to continue for a longer period of time, and thus the signal is generated more efficiently (Watowich et al., *supra*; Yoshimura et al., *Oncologist* 1(5):337-339 (1996);
25 Tilbrook et al., *Int. J. Biochem. Cell Biol.* 31(10):1001-1005 (1999); de la Chapelle et

al., *Proc. Natl. Acad. Sci. USA* 90(10):4495-4499 (1993); Kirby et al., *Cytokines Cell Mol. Ther.* 5(2):97-104 (1999); Yoshimura et al., *Curr. Opin. Hematol.* 5(3):171-176 (1998); Pharr et al., *Proc. Natl. Acad. Sci. USA* 90:938-942 (1993), incorporated herein by reference). According to one particularly preferred embodiment, a nucleic acid
5 encoding a hypersensitive EPOR is used as a gene therapeutic reagent to treat anemia. Alternatively, hypersensitive EPO receptors may be used to improve the athletic potential. Nonfunctional receptors can be similarly generated and tested for an absence of ligand stimulated response compared to the functional wild-type receptor. Such nonfunctional receptors may be used as treatments for polycythemia vera.

10 The present invention further provides a method of treating a mammal, preferably, a human, diagnosed with a particular disease, by administering a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor. In preferred embodiments, the nucleic acids of the invention are delivered to specific cells, tissues, or sites in a mammal suffering from a disease. In particularly preferred embodiments, the
15 nucleic acids of the invention are delivered *in vivo* to a specific site in the body. For example, the nucleic acids of the present invention may be administered (e.g., by injection) directly into a tumor for treatment of cancer. Alternatively, the nucleic acids of the invention may be administered to a particular diseased organ, for example, the liver or kidney. As but another example, the nucleic acids may be delivered to a patient
20 experiencing pain. Most preferably, therapeutic nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors are administered to a site at which a therapeutic benefit will be achieved. These sites include surfaces, such as skin, mucosal surfaces (e.g., in bronchial/nasal passages or genitourinary tract). Indeed, administration of nucleic acids to any bodily surface is particularly desirable. Typically, the inventive
25 nucleic acid is delivered to the cells of a mammal and expressed by those cells to

produce a polypeptide that spontaneously assembles into a supermolecular structure *in vivo* (e.g., in the lipid bilayer of a cell) and functions as a constitutively active, hypersensitive, or nonfunctional receptor.

In a related aspect, the present invention provides cells (*in vivo* or *in vitro*)
5 containing substantially pure nucleic acids encoding a constitutively active, hypersensitive, or nonfunctional receptor of the invention. In one preferred embodiment, the cells are transfected with the nucleic acid *in vitro* and transferred to a patient *in vivo* to achieve therapeutic benefit. Such methods of *ex vivo* gene therapy are described in detail below. One example of a receptor that is amenable to such an
10 approach is the human EPO receptor. A hypersensitive EPO receptor may be identified, such as the EPO receptor identified by Watowich et al. (*supra*), and transfected into human erythroid progenitor cells or bone marrow cells *in vitro*. The cells are then transferred to a patient diagnosed with anemia.

In yet another preferred embodiment, nucleic acids encoding constitutively
15 active, hypersensitive, or nonfunctional receptors are coadministered with an agonist or antagonist to the receptor in order to treat a mammal having a disease. Alternatively, an agonist or antagonist is administered subsequent to the administration of the nucleic acid. Such treatment is particularly desirable if either the nucleic acid or the agonist alone are insufficient to achieve therapeutic benefit.

20 A wide variety of *in vivo*, *in vitro*, and *ex vivo* nucleic acid delivery systems for administration of constitutively active, hypersensitive, or nonfunctional receptors are available in the art. One particularly preferred nucleic acid delivery system is the viral vector delivery system. Viral vectors are particularly useful for *in vivo* gene therapy. Alternatively, a wide variety of non-viral nucleic acid delivery systems are available in
25 the art. Such delivery systems are described in detail below.

In one preferred embodiment, a nucleic acid encoding any naturally constitutively active receptor (e.g., a wild-type receptor having constitutive activity) or any receptor having a mutation in its amino acid sequence that induces a higher basal activity than the corresponding wild-type receptor may be administered to a mammal to achieve therapeutic benefit. In another preferred embodiment, a nucleic acid encoding any receptor, e.g., a wild-type or mutant receptor, exhibiting hypersensitivity to a ligand may be administered to a mammal for the treatment of a particular disease. In yet another preferred embodiment, a nucleic acid encoding a nonfunctional receptor is administered to a mammal for treatment of a particular disease or condition.

10 Alternatively, the nucleic acid may be administered with the goal of improving the state of health in the mammal.

For example, clinically useful constitutively active receptors include GLP-1 receptors for diabetes, somatostatin receptors for cancer, EPO receptors for anemia, estrogen receptors for menopause, melanocortin receptors for obesity, β 2 adrenergic receptors for asthma etc. Similarly, examples of hypersensitive receptors that may be used in the present invention include the EPO receptors for anemia, mu opioid receptors for pain, estrogen receptors for menopause, melanocortin receptors for obesity, and β 2 adrenergic receptors for asthma.

15

A nucleic acid encoding a nonfunctional receptor that may be administered to a mammal for treatment of a particular disease includes, for example, a nonfunctional CCK-BR receptor for treatment of peptic ulcer disease, a nonfunctional growth factor receptor for treatment of cancer, a nonfunctional estrogen receptor as an alternative to the treatment of cancer with tamoxifen (e.g., replacing the effect of an estrogen receptor antagonist), a nonfunctional erythropoietin receptor for treatment of polycythemia vera, a nonfunctional cytokine receptor as an anti-inflammatory, or a nonfunctional CCR-3

20

25

receptor for treatment of asthma.

In certain preferred embodiments of the invention, it may be desirable to target a recombinant nucleic acid to a specific cell type or tissue *in vivo*. It will be appreciated by one of ordinary skill in the art that the viral and non-viral vectors of the invention may include, or encode for the purpose of expression, one or more cell-, tissue-, or organ-specific ligands (e.g., a protein or polypeptide) for the purpose of targeting the nucleic acid to any cell-type in the body. Preferably, the one or more cell-, tissue, or organ-specific ligands are presented on the outside surface of the viral or non-viral vector. The ligand functions to target the vector to a specific tissue *in vivo via* its affinity for a particular molecule expressed on the surface of the target cell. Alternatively, the ligand may be an antibody directed to a particular cellular protein, preferably a cellular protein expressed on the surface of a cell. As noted above, the specificity of the vector can be changed by simply changing the polypeptide or antibody ligand that is responsible for targeting.

Thus, in one preferred embodiment, the invention provides viral and non-viral vectors encoding constitutively active, hypersensitive, or nonfunctional receptors capable of targeting the receptor to a specific cell type in the body. In other preferred embodiments, targeting is accomplished by direct administration (e.g., by injection) of nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor to a cell, tissue, organ, or site of interest. Of course one skilled in the art will appreciate that the cell, tissue, or organ to which the vector is targeted can be altered by simply changing the cell-specific ligand on the vector.

In other preferred embodiments, it may be desirable to titrate the activity of the constitutively active or hypersensitive receptor of the invention, i.e., to decrease or reduce the level of signaling. Alternatively, the level of nonfunctional receptor

expressed in a cell may need to be controlled or altered, for example, to increase or decrease the inhibitory effect of the nonfunctional receptor. In order to achieve this result, the constitutively active, hypersensitive, or nonfunctional receptor is expressed under the control of an inducible promoter (e.g., the tetracycline inducible promoter).

5 Expression from the inducible promoter is regulated by a benign small molecule (e.g., tetracycline). Expression is increased or decreased by controlling the amount of the small molecule administered, or expression is turned on or off by addition or removal of the small molecule, respectively. Alternatively, it may be desirable to use a constitutive promoter to maintain a constant level of expression of the constitutively active receptor.

10 In yet another preferred embodiment, a tissue specific promoter may be used to target expression of a constitutively active, hypersensitive, or nonfunctional receptor to a particular tissue (see, for example, Gopalkrishnan et al., *Nucleic Acids Res.* 27(24):4775-4782 (1999); Huang et al., *Mol. Med.* 5(2):129-137 (1999)). Other inducible systems are widely available, e.g., the ecdysone inducible system (No et al., *Proc. Natl. Acad. Sci.*

15 *USA*, 93(8):3346-3351, (1996); Invitrogen, Carlsbad, CA).

Identifying Constitutively Active Receptors

The present invention provides a method of identifying constitutively active, hypersensitive, or nonfunctional receptors and nucleic acids encoding constitutively

20 active, hypersensitive, or nonfunctional receptors. Regarding constitutively active receptors, as described above, some receptors (e.g., wild-type receptors) are naturally constitutively active. Such naturally occurring constitutively active receptors are identified by simply comparing the basal activity of the wild-type receptor to that of a negative control. A suitable negative control is, for example, a cell lacking expression

25 of the natural wild type receptor (e.g., a cell transfected with an empty expression

vector, a cell transfected with a wild-type vector, or a cell transfected with a different receptor that has been previously established to lack constitutive activity (preferably both an empty expression vector and a non-constitutively active, wild-type vector are used)).

5 Alternatively, the present invention provides a method of identifying mutation-induced constitutively active, hypersensitive, or nonfunctional receptors. Preferably, the mutation-induced constitutively active, hypersensitive, or nonfunctional receptors are receptors of therapeutic interest. According to the present invention, mutation-induced receptors may be identified systematically by 1) identifying regions of
10 homology between a wild-type receptor (e.g., a nonconstitutively active, nonhypersensitive, or functional receptor) and one or more receptors with the preferred activity (i.e., constitutively active, hypersensitive, or nonfunctional receptors); 2) introducing mutations into one or more regions of the wild-type receptor based on the identified region(s) of homology; and 3) assaying the mutant receptors for constitutive,
15 hypersensitive, or nonfunctional activity. Methods of achieving each of these steps are described in detail below.

One skilled in the art will appreciate that the mutations can also be introduced by any random mutagenesis procedure standard in the art. A large variety of random mutagenesis kits are in fact commercially available. Once identified, e.g., in a
20 yeast expression system, the constitutive, hypersensitive, or nonfunctional activity of the receptor may be confirmed, for example, using a mammalian expression system. Alternatively, screening can be directly performed in a mammalian cell expression system.

As will be appreciated by those skilled in the art, numerous constitutively active and hypersensitive receptors (naturally occurring and non-naturally occurring) have been previously identified. Such receptors provide a wealth of information that can be used to identify additional constitutively active, hypersensitive, or nonfunctional receptors. To complete step 1) above, available nucleic acid and/or amino acid sequence information, preferably amino acid sequence information, including wild-type and mutant receptors, is compiled to generate a database of constitutively active, hypersensitive, or nonfunctional receptor sequences. Next, the sequence of a given receptor (including any orphan receptor, non constitutively active receptor, non hypersensitive receptor, or functional receptor) of therapeutic interest (e.g., a receptor known to be a receptor for an agonist) is compared to the many sequences of constitutively active, hypersensitive, or nonfunctional receptors in the particular database to identify regions that are conserved between the receptor of therapeutic interest and the one or more constitutively active, hypersensitive, or nonfunctional receptors. The present invention demonstrates step 1) by providing an extensive database of constitutively active Class A G protein-coupled receptors (see Fig. 1). One of ordinary skill in the art will appreciate that additional databases may easily be generated for other types of receptor molecules, for example, Class B G protein-coupled receptors (see Jüppner et al., *Curr. Opin. Nephrol. Hypertens.* 3(4):371-378, Fig. 1, p 373 (1994)).

In order to complete step 2), for example, specific residues in a nonconstitutively active wild-type receptor are targeted for mutation based on the identified regions of homology between the nonconstitutively active receptor and constitutively active receptor(s), which are likely to impart constitutive activity onto the nonconstitutively active receptor. For example, if a region of homology between a

nonconstitutively active receptor and a constitutively active receptor is identified that is identical in all amino acids but one, a mutation is introduced into the nonconstitutively active receptor to make the conserved region in the nonconstitutively active receptor identical to that of the constitutively active receptor. Alternatively, if the region
5 conserved between the nonconstitutively active receptor and the constitutively active receptor shows a high degree of amino acid similarity, a series of targeted mutations are introduced into the nonconstitutively active receptor that are likely, based on the degree of homology and the knowledge of the skilled artisan, to make the receptor constitutively active. As but another example, the nonconstitutively active receptor
10 might share a region of homology with another nonconstitutively active receptor that has been made constitutively active by the introduction of a certain mutation or mutations. In this case, the same or similar mutations are introduced into the given nonconstitutively active receptor.

Similarly, one skilled in the art will appreciate that in order to complete step
15 2) with a hypersensitive receptor, the same steps described above for a constitutively active receptor would be carried out for a hypersensitive receptor. For example, specific residues in a nonhypersensitive wild-type receptor are targeted for mutation based on the identified regions of homology between the nonhypersensitive receptor and hypersensitive receptor(s), which are likely to impart hypersensitivity onto the
20 nonhypersensitive receptor. The candidate hypersensitive receptors are then stimulated with a low concentration of ligand (below saturating levels of ligand) and the receptor induced signal is measured. An increase in ligand-stimulated activity compared to the wild-type receptor indicates the identification of a hypersensitive receptor. A nonfunctional receptor may be similarly generated and tested for an absence or decrease
25 in ligand-stimulated activity compared to the functional, wild-type receptor.

Alternatively, the database is used to identify regions of homology between a naturally occurring receptor of therapeutic interest and one or more constitutively active, hypersensitive, or nonfunctional receptors. The identified regions of homology would lead the skilled artisan to test the naturally occurring receptor for constitutive,
5 hypersensitive, or non functional activity.

Applicants demonstrate step 2) by using the database of constitutively active Class A G protein-coupled receptors provided in step 1) (Fig. 1) to target specific residues in nonconstitutively active receptors for mutation. Briefly, highly conserved regions were identified between several nonconstitutively active receptors and a number
10 of constitutively active Class A G protein-coupled receptors in the database. This information was used to target specific residues in the nonconstitutively active receptors for mutation. As described in detail below, targeted point mutations were introduced into the cholecystokinin-B/gastrin receptor (CCK-BR), the MC-4 receptor, and the mu opioid receptor which imparted constitutive activity to the nonconstitutively active
15 receptors (see Examples 1, 2, and 3). It will be appreciated that this method of comparing nonconstitutively active receptors and constitutively active receptors to identify regions of conservation may be repeated with any family of related receptors with the goal of targeting regions of homology for mutation, as set forth in steps 1) and 2) above.

20 Step 3) involves assaying the mutant receptors for constitutive, hypersensitive, or nonfunctional activity by assaying for an increase in basal activity of the receptor. Of course, it will be appreciated that the constitutive activity, hypersensitivity, or lack of activity, respectively, of a particular receptor can be measured by any assay typically used to measure the basal and/or ligand-stimulated
25 activity of the receptor. Any receptor of therapeutic interest will have such an associated

assay, and such examples are provided herein (see Examples 1-10). To name but a few, changes in basal level second messenger signaling may be assessed to identify constitutively active receptors, including, but not limited to changes in basal levels of cAMP, cGMP, ppGpp, inositol phosphate, or calcium ion.

5 As but one example, ligand-dependent activation of the melanocortin-4 (MC-4) receptor is assayed by measuring an increase in cAMP production (Huszar et al., *Cell* 88:131-141, (1997)). The present invention demonstrates the use of this assay to identify a constitutively active MC-4 receptor (see Fig. 2). Specifically, the assay detected an increase in basal level cAMP production in a mutant MC-4 receptor; this
10 mutant receptor was generated based on the homology of the wild-type MC-4 receptor to other constitutively active Class A G protein-coupled receptors.

 These simple principles can easily be applied to identify additional constitutively active G protein-coupled receptors. For example, similar studies that measured increases in intracellular cAMP were carried out to identify constitutively
15 active mutants of the pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) (Cao et al., *FEBS Lett.*, Mar 10;469(2-3):142-146, (2000)). As but another example, the constitutively active mutants of the β 2 bradykinin (BK) receptor and the AT1A angiotensin I and II receptors were identified by measuring inositol phosphate production (Marie et al., *Mol. Pharmacol.* 1:92-101, (1999); Groblewski et al., *J. Biol.*
20 *Chem.*, 272(3):1822-1826, (1997); Feng et al., *Biochemistry*, 37(45):15791-15798 (1998)). A constitutively active CCK-BR was also identified by measuring basal inositol phosphate production (Beinborn et al., *J. Biol. Chem.* 273(23): 14146-14151 (1998); and Fig. 1). Mutants of CCK-BR were tested by simply comparing the basal level of inositol phosphate production of a mutant CCK-BR to the basal level inositol
25 phosphate production of the wild-type CCK-BR to determine whether the mutant CCK-

BR was constitutively active.

Additional examples of G protein-coupled receptors having intracellular second messenger signaling pathways that may be evaluated to identify constitutively active forms of receptors include the GLP-1 receptor (adenylate cyclase and phospholipase C (PLC)) and the parathyroid hormone receptor (PTH) (see Dillon et al., *Endocrinology* 133(4):1907-1910, (1993); Whitfield and Morley, *TIPS*, 16:382-385, 1995). Other G protein-coupled receptors bind to certain intracellular molecules in their activated states. For example, the mu opioid receptor induces an increased level of GTP binding by receptor-activated G protein (G α i) (see, e.g., Befort et al., *J. Biol. Chem.* 274(26):18574-18581, (1999)).

The activity of other types of receptors (e.g., non-G protein-coupled receptors such as single transmembrane domain receptors and nuclear receptors) can also be measured *via* the biochemical pathway they induce. For example, binding of the ligand EPO to the EPO receptor activates the JAK2-STAT5 signaling pathway (see, e.g., Yoshimura et al., *Curr. Opin. Hematol.*, 5(3):171-176, 1998). The basal and stimulated levels of JAK2 and STAT5 signaling can easily be assessed by one of ordinary skill in the art, as described in Yoshimura et al., *supra*, to identify constitutively active (or hypersensitive) EPO receptors.

As an alternative to measuring molecules in a signaling pathway directly to identify constitutively active, hypersensitive, and nonfunctional receptors, a reporter assay system may be established in which a response element, responsive to signaling through a particular receptor, is attached to a reporter gene in combination with a transcriptional promoter. Specifically, the expression of the reporter gene is controlled by the activity of the chosen receptor. This method involves the steps of 1) identifying a response element that is sensitive to signaling by a specific receptor polypeptide (e.g., by

eliciting an increase or decrease in gene expression upon receptor activation); 2)
operably linking the response element and a promoter to a reporter gene; and 3)
comparing the basal or ligand-stimulated reporter activity of a candidate receptor to a
negative control. An increase in the basal level reporter activity compared to the
5 negative control indicates the identification of a constitutively active receptor.
Similarly, an increase in ligand stimulated activity, compared to the negative control,
indicates the identification of a hypersensitive receptor, and an absence of ligand-
stimulated activity, compared to a corresponding functional receptor, indicates the
identification of a nonfunctional receptor. It is important to note that hypersensitive
10 receptors may not necessarily have any detectable increase in basal activity. In preferred
embodiments, this assay system is used to screen for receptor mutants exhibiting
constitutive, hypersensitive, or nonfunctional activity.

It will be appreciated that the receptor can be any receptor identified as a
candidate constitutively active, hypersensitive, or nonfunctional receptor. In addition,
15 one skilled in the art will recognize that the response element used in the present
response assay can be any response element that is sensitive to signaling through the
identified candidate receptor. For example, in reporter assays for identifying
constitutively active receptors that are coupled to different G proteins, one would select
response elements that are sensitive to signaling downstream of respective G proteins.
20 Examples of preferred response elements include a portion of the somatostatin promoter
(which has included a number of different response elements) (SMS), the serum
response element (SRE), and the cAMP response element (CRE), which are response
elements sensitive to G protein-coupled receptor signaling. Other preferred response
elements include response elements sensitive to signaling through a single
25 transmembrane receptor or a nuclear receptor. In particular examples, SMS is activated

by coupling of receptors to either $G\alpha_q$ or $G\alpha_s$; SRE is activated by receptor coupling to $G\alpha_q$; and CRE is activated by receptor coupling to $G\alpha_s$ and inhibited by coupling to $G\alpha_i$; and the TPA response element (sensitive to phorbol esters) is activated by receptor coupling to $G\alpha_q$. Each of these response elements can be employed in a reporter assay
5 to generate a readout for the basal and ligand-stimulated activity of a specific G protein-coupled receptor.

More generally, a reporter construct for detecting receptor signaling might include a response element that is a promoter sensitive to signaling through a particular receptor. For example, the promoters of genes encoding epidermal growth factor,
10 gastrin, or fos can be operably linked to a reporter gene for detection of G protein-coupled receptor signaling. Another example includes the TPA response element, which is sensitive to phorbol ester induction.

It will be appreciated that a wide variety of reporter constructs can be generated that are sensitive to any of a variety of signaling pathways induced by
15 signaling through a particular receptor (e.g., a second messenger signaling pathway). Accordingly, this assay system may be used to identify other types of constitutively active, hypersensitive, or nonfunctional receptors, including receptors that are single transmembrane receptors or nuclear receptors, by simply selecting a response element that is sensitive to the particular receptor and positioning the response element upstream
20 of a reporter gene in a reporter construct. For example, the elements AP-1, NF- κ b, SRF, MAP kinase, p53, c-jun, TARE can all be positioned upstream of a reporter gene to obtain reporter gene expression. Additional response elements, including promoter elements, can be found in the Stratagene catalog (PathDetect® in Vivo Signal Transduction Pathway cis-Reporting Systems Introduction Manual or PathDetect® in
25 Vivo Signal Transduction Pathway trans-Reporting Systems Introduction Manual,

Stratagene, La Jolla, CA).

In preferred embodiments, the G protein-coupled reporter assay system includes 1) a reporter construct containing a response element that is sensitive to signaling through a specific G protein, and a promoter, operably linked to a reporter
5 gene; preferably in combination with 2) an expression vector containing a promoter operably linked to a nucleic acid encoding a receptor, wherein the receptor is coupled to a G protein or other downstream mediator to which the selected response element is sensitive. Alternatively, a G protein-coupled receptor assay includes transfection of wild-type or polymorphic receptors into cells followed by assessment of the levels of
10 transcription of cell specific genes compared to the appropriate controls (e.g., transfected cells compared to nontransfected cells and the presence or absence of ligand stimulation).

The experiments described herein demonstrate the use of specific response elements that are sensitive to signaling through each of $G\alpha_q$, $G\alpha_s$, and $G\alpha_i$. For
15 example, the SMS and SRE response elements each detect an increase in basal activity of the Leu325Glu CCK-BR mutant receptor, which is coupled to $G\alpha_q$ (see Fig. 3). Similarly, a constitutively active rat mu opioid receptor was identified using a reporter construct sensitive to $G\alpha_i$ coupling (see Fig. 4). The response element employed in this assay was the cAMP-response element (CRE), which is sensitive to $G\alpha_i$ mediated
20 reductions in intracellular levels of cAMP. Signaling through the rat mu opioid receptor *via* $G\alpha_i$ inhibits adenylate cyclase, causing a decrease in intracellular cellular cAMP. Therefore, an increase in rat mu opioid receptor signaling induces a decrease in CRE mediated reporter activity.

Mutation induced G α i-mediated decreases in intracellular cAMP were, prior to the present invention, more often measured by 1) stimulating cells with forskolin, which causes receptor-independent activation of adenylate cyclase and generates an intracellular pool of cAMP; 2) stimulating the cells with ligand; and 3) measuring the ligand-induced, receptor-dependent G α i-mediated decrease in the intracellular cAMP pool (e.g., using a radioimmunoassay (e.g., New England Nuclear, Boston, MA)). As demonstrated herein, the reporter system approach was capable of identifying a constitutively active rat mu opioid receptor (Fig. 4). Specifically, cells transfected with a CRE-Luc reporter construct (Stratagene, La Jolla, CA) and an expression vector encoding either a wild-type or a mutant rat mu opioid receptor were stimulated with 0.5 μ M or 2 μ M forskolin to increase the intracellular pool of cAMP. The basal (and ligand-induced) level of receptor activity was then measured using a standard luciferase assay (see Fig. 4). Coexpression of the receptor of interest with a luciferase reporter gene construct allows one to measure light emission as a readout for basal signaling.

The results illustrated in Fig. 4 show a reduction in basal activity (i.e., forskolin-induced cAMP production in the absence of receptor stimulation) when the expressed mutant rat mu opioid receptor is compared to the basal activity of the expressed wild-type rat mu opioid receptor. This decrease in activity indicates an increase in the basal level activity of the mutant rat mu opioid receptor, because activation of the rat mu opioid receptor induces a decrease in CRE-mediated reporter activity (Fig. 4, compare 0.5 μ M wild-type vs. 0.5 μ M mutant and 2 μ M wild-type vs. 2 μ M mutant).

It is important to note that the level of constitutive activity in the mutant rat mu opioid receptor is increased to 50% of the level of ligand-stimulated activity of the wild-type receptor. This high level of inhibitory signaling supports the hypothesis that

constitutively active receptors, introduced by gene therapy, are likely to transduce a sufficient intracellular signal to reduce pain *in vivo*. According to the present invention, even low levels of basal signaling may mimic the effect of the ligand-stimulated signaling achieved with endogenous concentrations of agonist. For example, the signal transduced in a cell *in vivo* is likely to be less than the ligand-stimulated signal measured experimentally. This may be due to the low *in vivo* concentrations of endogenous ligand or to the low *in vivo* levels of expression of the receptor on the surfaces of cells. It will be appreciated that these features can be manipulated to control the level of constitutive activity transduced by the cell. For example, for a weak constitutively active receptor, the level of expression can be increased to achieve increased signaling, for example, by selecting a strong constitutive promoter. Alternatively, for a strong constitutive receptor, a high level of expression might not be required to achieve sufficient signaling. Alternatively, signaling might be diminished by reducing the level of expression of the strong constitutively active receptor.

Although successful, use of the prior method of measuring G α i coupling has several disadvantages. First, detecting G α i mediated inhibition of cAMP requires overcoming the simultaneous positive effects of forskolin on adenylate cyclase. For example, Fig. 5 illustrates the positive effect of forskolin in HEK293 cells on the response of CRE-Luc in the absence of a contransected receptor protein. In addition, detection of a ligand-stimulated decrease in intracellular cAMP relies on whether a large enough percentage of the cells are successfully transfected with, and express, the receptor molecule. Moreover, when using transient transfection assays, interexperimental variation occurs because the percentage of cells transfected from one experiment to the next is difficult to control.

A positive assay for G α i coupling (i.e., one that yields an increase in luciferase activity upon receptor activation, instead of a negative assay, one that yields a decrease in luciferase activity upon receptor activation), provides a detectable output signal and less interassay variation. It was hypothesized that G α i coupling could be detected by altering the signaling pathway generated by G α i coupled receptors. A chimeric G protein (Gqi5, Broach and Thorner, *Nature* 384 (Suppl.):14-16 (1996)) that contains the entire G α q protein having five C-terminal amino acids from G α i attached to the C-terminus of G α q has been generated. This chimeric G protein is recognized as G α i by G α i coupled receptors, but switches the receptor induced signaling from G α i to G α q. This allows G α i receptor coupling to be detected using a positive assay by use of the G α q responsive SMS-Luc or SRE-Luc construct (Stratagene, La Jolla, CA). SMS and SRE preferably respond to G α q mediated inositol and calcium production. Moreover, detection can be carried out in the absence of forskolin pre-stimulation of cells.

As demonstrated in Fig. 6, Gq5i can be used to detect rat mu opioid receptor coupling to G α i. Fig. 6 shows that no ligand-stimulated luciferase activity is detected in response to ligand stimulation using luciferase constructs having either the SMS or SRE alone (left two columns), whereas a large increase in ligand-stimulated luciferase activity is detected using SRE-Luc in combination with Gq5i (far right). This assay was also employed to measure the constitutive activity of the Asn150Ala mutant rat mu opioid receptor (Fig. 7).

One skilled in the art will appreciate that the assays described herein for the various constitutively active receptors can also be applied in the identification of hypersensitive or nonfunctional receptors. More particularly, any assay that measures the ligand-stimulated response of a particular receptor can be used to identify

hypersensitive or nonfunctional receptors. For example, a hypersensitive receptor may be identified by exhibiting a ligand-dependent increase in intracellular signaling compared to the wild-type receptor. More specifically, a hypersensitive receptor may be characterized in that it exhibits an increased response to a specific concentration of ligand, compared to the response of a wild-type receptor to the same concentration of ligand. For example if 5 μ M ligand induces a 5-fold stimulation of activity in a wild-type receptor, compared to a negative control, 5 μ M ligand may stimulate a 10-fold stimulation in activity in a hypersensitive receptor, compared to the same negative control. As noted above, a hypersensitive EPO receptor has been identified using such assays (Watowich et al. *supra*).

Furthermore, a number of examples are provided herein that illustrate the ease with which these and similar approaches can be applied to identify non-G protein-coupled constitutively active, hypersensitive, or nonfunctional receptors, including, constitutively active, hypersensitive, or nonfunctional single transmembrane domain receptors (e.g., EPOR, see Example 11) and nuclear receptors (steroid hormone receptors, see Example 10).

Mu Opioid Receptor

According to one preferred embodiment of the present invention, nucleic acids are identified that encode clinically useful constitutively active receptors. We demonstrate this aspect of the invention by identifying a constitutively active mu opioid receptor. It is important to note that the mu opioid receptor of the invention is also hypersensitive. For example, the affinity of the mu opioid receptor for the ligand DAMGO is increased (see Fig. 15, which shows that a mutation that confers constitutive activity to the mu opioid receptor also confers hypersensitivity; the mutant receptor is

responsive to a lower concentration of ligand than the wild-type receptor).

The mu opioid receptor is an opiate receptor that falls within the G protein-linked seven transmembrane domain neuropeptide receptor family. In general, opiate receptors (including μ (mu), κ , δ , and opiate-like receptor (OLR)) couple to guanine nucleotide binding (G) proteins (Li et al. *supra*). For example, opiates can alter GTP hydrolysis, GTP analogs and pertussis toxin can change opiate receptor binding, and opiates can influence G-protein-linked second messenger systems and ion channels. More specifically, mu opioid receptors have a characteristic high affinity for morphine and other opiate drugs and peptides. Binding of morphine to the mu opioid receptor results in an analgesic and euphoric effect, common to opiate drugs. In the present invention, the mu opioid receptor is of particular interest because of its analgesic properties. The present invention provides a method of administering a nucleic acid encoding a constitutively active morphine receptor to a patient in pain to provide significant relief from the pain, while reducing the side effects experienced upon administration of morphine.

A single point mutation (Asn to Ala at amino acid 150) was introduced into the third transmembrane region of the rat mu opioid receptor (SEQ ID NO: 1). This Asn residue was targeted for mutation based on it being highly conserved between the mu opioid receptor, the bradykinin B2 receptor, and the angiotensin II AT1A receptor. Furthermore, homologous mutations at this residue in the bradykinin B2 and angiotensin II AT1A receptors yielded receptors having constitutive activity. Indeed, the Asn150Ala mu opioid receptor mutant exhibited levels of basal activity, which exceeded 50% of the maximal level of ligand-stimulated second messenger signaling (see Example 1).

According to the present invention, the constitutively active mu opioid receptor described herein may be inserted into any of a variety of known viral and non-viral vectors and administered to a particular cell, tissue, or site in a mammal to obtain therapeutic benefit. A particularly preferred viral vector is the adenoviral vector. In fact, the adenoviral vector has been used previously for gene therapy to reduce pain and to introduce genes of interest into the intrathecal space (the fluid that bathes the spinal cord) (see Burcin et al., *Proc. Natl. Acad. Sci. USA* 96:355-360, (1999); Finegold et al., *Human Gene Therapy* 10:1251-1257, (1999); Vasquez et al., *Hypertension* October Part II 756-761 (1999); Mannes et al., *Brain Research* 793:1-6, (1998)).

In preferred embodiments, expression of the constitutively active mu receptor results in an analgesic response at the site of administration. In one particularly preferred embodiment, a virally encoded constitutively active mu opioid receptor is used to treat patients with chronic back pain resulting from any etiology, including fracture or metastatic disease. Alternatively, the pain is due to arthritis or other inflammatory diseases. For example, an adenoviral construct encoding the constitutively active mu opioid receptor may be administered into the intrathecal space for treatment of pain, for example, back pain. It will be appreciated that a nucleic acid encoding a constitutively active mu opioid receptor may be delivered to a patient experiencing pain in any location in the body.

Also included is the administration of constitutively active, hypersensitive, or nonfunctional allelic variations, natural mutants, or induced mutants of mu opioid receptors. Of particular interest are mu opioid receptor mutants in which the mutation is at or near the region surrounding the N residue at position 150 of SEQ ID NO: 1, at or surrounding the DRY motif, at positions 154-156 of SEQ ID NO:1, or at or surrounding positions 13 and 20 residues N-terminal to the CWLP motif of SEQ ID NO: 1. The

invention also includes the use of nucleic acids encoding chimeric polypeptides that contain, as part of the chimera, the mu opioid receptor polypeptide (e.g., in addition to G protein).

The invention further includes nucleic acids encoding any constitutively
5 active or hypersensitive fragment or analog of the mu opioid receptor, or any other constitutively active receptor identified by methods described herein. A constitutively active fragment or analog of the mu opioid receptor possesses *in vivo* or *in vitro* basal activity, which is greater than the wild-type basal activity (see in Figs. 13, 14 and 7, and SEQ ID NO: 1). A useful constitutively active mu opioid receptor fragment or
10 constitutively active mu opioid receptor analog is one that exhibits constitutive biological activity in any biological assay for mu opioid receptor activity (for example, those assays described in Example 1).

It will be appreciated that nucleic acids encoding any constitutively active, hypersensitive, or nonfunctional receptor, e.g., any Class A G protein-coupled receptor
15 (e.g., MC-4 or CCK-BR) or Class B G protein-coupled receptor (GLP-1 or PTH), any single transmembrane domain receptor (e.g., EPOR), or any nuclear receptor (e.g., steroid hormone receptors, such as the estrogen receptor), can also be utilized as gene therapeutic agents, and such is within the ability of one skilled in the art.

20 *Viral Vectors for Gene Delivery*

Viral vectors are primary gene transfer tools for gene therapy and other gene transfer applications using both *ex vivo* and *in vivo* protocols. Viral vectors, particularly retroviral vectors with the appropriate tropisms for the selected cells are particularly useful for therapeutic delivery of nucleic acids and may be used as gene transfer delivery
25 systems for the constitutively active, hypersensitive, or nonfunctional receptors of the

present invention. Numerous vectors useful for this purpose are generally known and have been described (Miller, *Human Gene Therapy* 15:14 (1990); Friedman, *Science* 244:1275-1281 (1989); Eglitis and Anderson, *BioTechniques* 6:608-614 (1988); Tolstoshev and Anderson, *Current Opinion in Biotechnology* 1:55-61 (1990); Sharp, *The Lancet* 337:1277-1278 (1991); Cornetta et al., *Nucleic Acid Research and Molecular Biology* 36:311-322 (1987); Anderson, *Science* 226:401-409 (1984); Moen, *Blood Cells* 17:407-416 (1991); and Miller and Rosman, *Biotechniques* 7:980-990(1989)) incorporated by reference herein. Retroviral vectors are particularly well developed and have been used in the clinical setting to provide therapeutic benefit (Rosenberg et al., *N. Engl. J. Med* 323:370 (1990)).

Viral vectors of the present invention include viral nucleic acids (e.g., DNA or RNA) that have been modified to serve as vectors for nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors. Viral vectors of the present invention include any viral vector having the ability to transfer (or “transduce”) a nucleic acid to a cell by infecting that cell. Viral vectors which may be utilized in the present invention include adenoviral vectors and adeno-associated virus-derived vectors (Burcin et al., *supra*; Finegold et al., *supra*; Vasquez et al. *supra*; Mannes et al. *supra*; Ilan et al., *Seminars in Liver Disease*, 19:49-59, (1999); Patijn et al., *Seminars in Liver Disease* 19:61-39, 1999), retroviral vectors (e.g., Moloney Murine Leukemia virus based vectors, Spleen Necrosis Virus based vectors, Friend Murine Leukemia based vectors (Ganjam, *Seminars in Liver Disease*, 19:27-37 (1999)), lentiviral based vectors (Human Immunodeficiency Virus based vectors etc.), papova virus based vectors (e.g., SV40 viral vectors, see e.g., Strayer et al., *Seminars in Liver Disease*, 19:71-81 (1999), Herpes-Virus based vectors, viral vectors that contain or display the Vesicular Stomatitis Virus G-glycoprotein Spike, Semi-Forest virus based vectors, Hepadnavirus based

vectors, and Baculovirus based vectors. Particularly preferred viral vectors include adenoviral vectors. Moreover, the technique of the present invention is not limited to gene-delivery vectors, but also to whole, naturally occurring viruses upon which the above-mentioned vectors are based. The adenoviral vector delivery system for nucleic acids encoding the mu opioid or other constitutively active, hypersensitive, or nonfunctional receptors is particularly useful because the adenovirus has been shown to be easily distributed to a particular site upon direct injection to that site (including neuronal sites like the intrathecal space, see Finegold et al., *supra* and Mannes et al. *supra*).

10 The retroviral constructs, packaging cell lines, and delivery systems which may be useful for this purpose include, but are not limited to, one, or a combination of the following: self inactivating vectors; double copy vectors; selection marker vectors; and suicide mechanism vectors.

Fragments or analogs of the constitutively active mu opioid or other receptors of the invention, may also be administered by any suitable viral vector system. Useful fragments or analogs of the mu opioid or other receptor may be administered by inserting the nucleic acid encoding the fragment or analog in place of the full length receptor gene into a gene therapy vector.

In preferred embodiments, a standard *ex vivo* viral gene therapy procedure may be useful in treating a mammal diagnosed with a disease. In *ex vivo* gene therapy, a specific cell type or tissue is removed from a subject and genetically engineered *in vitro* using viral gene transfer vectors. The genetically engineered cell or tissue is subsequently returned to the subject. In this type of gene therapy protocol, highly infectious viral vectors with broad tropisms, such as those with amphotropic envelope glycoprotein are particularly useful, (e.g., glycoprotein of the Moloney murine leukemia

25

virus or glycoprotein G of the vesicular stomatitis virus (VSVG)). For example, in one preferred embodiment, a constitutively active, hypersensitive, or nonfunctional receptor of the present invention is administered to a subject using *ex vivo* gene therapy by (i) transfecting a selected cell type *in vitro* with nucleic acid encoding the selected receptor; 5 (ii) allowing the cells to express the receptor; and (iii) administering the modified cells to an individual to generate a therapeutic effect in the individual.

Retroviral delivery of constitutively active, hypersensitive, or nonfunctional receptors, or other forms of gene transfer are also particularly appropriate for treatment of cancer (e.g., a constitutively active somatostatin receptor, or a nonfunctional growth 10 factor receptor, to reduce growth of cancer cells), neoplasms of the immune system, as removal, treatment, and re-implantation of hematopoietic cells is a matter of course for the treatment of these neoplasms. Standard techniques for the delivery of gene therapy vectors may be used to transfect stem cells. Such transfection may result in cells that synthesize a constitutively active, hypersensitive, or nonfunctional receptor useful in 15 lowering the recurrence rate of the neoplasm in the patient.

Non-Viral Gene Delivery

A wide variety of non-viral nucleic acid delivery techniques that can be used *in vitro*, *in vivo*, or *ex vivo* are also well known in the art. Nucleic acids encoding 20 constitutively active, hypersensitive, or nonfunctional receptors, e.g., the mu opioid receptor, or a fragment or analog thereof, under the regulation of the appropriate promoter, and including the appropriate sequences required for insertion into genomic DNA of the patient, or autonomous replication, may be administered to the patient using the following gene transfer techniques: microinjection (Wolff et al., *Science* 247:1465 25 (1990)); calcium phosphate transfer (Graham and Van der Eb, *Virology* 52:456 (1973));

Wigler et al., *Cell* 14:725 (1978)); Felgner et al., *Proc. Natl. Acad. Sci. USA* 84:7413 (1987)); lipofection (Felger et al., *supra*; Ono et al., *Neuroscience Lett.* 117:259 (1990)); Brigham et al., *Am. J. Med. Sci.* 298:278 (1989)); Staubinger and Papahadjopoulos, *Meth. Enz.* 101:512 (1983)) asialorosonucoid-polylysine conjugation (Wu and Wu, *J. Biol. Chem.* 263:14621 (1998)); Wu et al., *J. Biol. Chem.* 264:16985 (1989)); electroporation (Neumnn et al., *EMBO J.* 7:841 (1980)); and receptor mediated endocytosis of DNA (Smith et al., *Seminars in Liver Disease* 19:83-92 (1999)). These references are hereby incorporated by reference.

For example, the nucleic acids encoding the constitutively active, hypersensitive, or nonfunctional receptors of the present invention may be associated with liposomes, e.g., such as lecithin liposomes or other liposomes known in the art, e.g., nucleic acid liposomes (for example, as described in WO 93/24640, incorporated herein by reference). Liposomes that include cationic lipids interact spontaneously and rapidly with polyanions, such as DNA and RNA, resulting in liposome/nucleic acid complexes. In addition, the polycationic complexes fuse with cell membranes, resulting in an intracellular delivery of polynucleotides that bypasses the degradative enzymes of the lysosomal compartment. This may be of particular use for administering RNA molecules. Published PCT application WO 94/27435, incorporated herein by reference, describes compositions for genetic immunization that include cationic lipids and polynucleotides. Agents that assist in the cellular uptake of nucleic acid, such as calcium ions, viral proteins, and other transfection facilitating agents, may advantageously be used.

Therapeutic Compositions

The present invention further provides compositions that include nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors in a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers for use with
5 the invention include aqueous solutions, non-toxic excipients, including water saline, dextrose, glycerol ethanol, buffers, and the like, (and combinations thereof) as described in *Remington's Pharmaceutical Sciences*, 15th Ed. Easton: Mack Publishing Co. pp. 1405-1412 and 1461-1487 (1975) and *The National Formulary XI*, 14th Ed. Washington: American Pharmaceutical Association (1975), the contents of which are
10 incorporated herein by reference. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil and injectable organic esters such as ethyloleate. Aqueous carriers include water, alcoholic/aqueous solutions, saline solutions, parenteral vehicles such as sodium chloride, Ringer's dextrose, etc. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include
15 antimicrobials, anti-oxidants, chelating agents, and inert agents. The pH and exact concentration are adjusted according to routine skills in the art. See *Goodman and Gilman's The Pharmacological Basis for Therapeutics* (7th Ed.).

As described above, the compositions of the present invention may be administered to a mammal. The examples set forth herein demonstrate use of the
20 invention in cells *in vitro*. However, the results disclosed herein are transferable to any mammal of interest. For example, both the constitutively active CCK-BR receptor and the rat mu opioid receptor exhibit increased basal level activities in the absence of ligand (see Fig. 3, SMS-Luc results and Fig. 7), indicating that the constitutively active receptors are likely to generate a signal that mimics the normal, endogenous ligand-
25 induced activity. In preferred embodiments, the compositions of the invention are used

to treat humans. In addition, the compositions of the present invention may be used in veterinary medicine (e.g., to treat canines, felines, bovines, livestock, or zoo animals). One skilled in the art would recognize that any composition that is safe and effective in animals may also be administered to humans using similar dose parameters.

5 In preferred embodiments, the composition is administered to an individual in need of treatment (e.g., an individual diagnosed with a particular disease or disorder). In one preferred embodiment, nucleic acid delivery may be achieved by means of an accelerated particle gene transfer gun. The technique of accelerated particle gene delivery is based on the coating of nucleic acid to be delivered into cells onto extremely
10 small carrier particles, which are designed to be small in relation to the cells sought to be transformed by the process. The nucleic acid encoding the desired gene sequence may be simply dried onto a small inert particle. The particle may be made of any inert material such as an inert metal (gold, silver, platinum, tungsten, etc.) or inert plastic (polystyrene, polypropylene, polycarbonate, etc.). Preferably, the particle is made of
15 gold, platinum or tungsten. Most preferably the particle is made of gold. Gene guns are commercially available and well known in the art, for example, see U.S. Patent No. 4,949,050; U.S. Patent No. 5, 120,657 (available from PowderJect Vaccines, Inc. Madison WI); or U.S. Patent No. 5,149, 655.

 Alternatively, the composition described herein can be administered by any
20 of a variety of routes including intravenously, (IV), intramuscularly (IM), intraperitoneal (IP), and subcutaneously. The inventive composition may be administered to mucosal surfaces by, for example, the nasal or oral (intra gastric) route. Additionally, the composition may be administered using a suppository, transdermal patch, or alternatively by inhalation therapy.

25

Administration of the inventive compositions occurs in a manner compatible with the dosage formulation and in such amount as will be therapeutically effective. In the case of gene delivery, a dose formulation will be delivered in such amount that will produce an identifiable gene product (i.e., as detected directly (e.g., by ELISA) or by an assay for the biological activity of the gene product in the treated subject). The quantity of viral vector, or other gene delivery vehicle administered depends on the characteristics of the delivery vehicle and the characteristics of the subject to be treated. Precise amounts of the composition to be administered may depend on the judgment of the practitioner and may be particular to each subject and antigen. The dosage may also depend on the route of administration and will vary according to the size (i.e., weight) of the host. However, suitable dosage ranges are determined by one skilled in the art and may be of the order of 1 ng to 10 µg for naked DNA (e.g., if delivery of the nucleic acid is to occur *via* a gene gun) and 1 million to 1 billion plaque forming units (PFU) for other viral *in vivo* methods of nucleic acid delivery.

Suitable dose regimes are also variable, but may include an initial administration followed by any number of subsequent administrations. For example, the composition may include a single dose schedule, or a multiple dose schedule in which a primary course of administration may be 1-10 separate doses, followed by additional administrations given at subsequent time intervals required to maintain expression of the constitutively active, hypersensitive, or nonfunctional receptor, for example, at a given interval of months or years for a second administration, and if needed, a subsequent administration(s) after several months or years. Examples of suitable administration schedules include a monthly or bi-monthly schedule, as long as the treatment is required (e.g., over a lifetime), or other schedules sufficient to maintain receptor expression to reduce or eliminate the disease symptoms or severity. Alternatively, the treatment of the

present invention can be administered to achieve prevention of a particular disease or condition, or increased health (e.g., improved physiology, increased life span etc.). One important factor that governs the administration schedule is the amount of time that the receptor is expressed in the tissue. The dosage and administration procedure used in mice and other animal models can be scaled to humans or other animals by one skilled in the art.

Monitoring Expression

Successful expression of the constitutively active, hypersensitive, or nonfunctional receptor polypeptides of the invention in a cell or tissue can be assessed by standard immunological assays, for example the ELISA (see, Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, New York, V. 1-3, 2000; Harlow and Lane, *Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, incorporated herein by reference).

Alternatively, the biological activity of the gene product of interest can be measured directly by the appropriate assay, for example, the assays provided herein. The skilled artisan would be able to select and successfully carry out the appropriate assay to assess the biological activity of the gene product of interest in a particular sample. Such assays (e.g., radioligand binding or receptor signaling assays) might require removing a sample (e.g., cells or tissue) from the individual to use in the assay. Expression of the particular receptor may be monitored by any of a variety of immunodetection methods available in the art. For example, the receptor may be detected directly using an antibody directed to the receptor itself or an antibody directed to an epitope tag (e.g., a FLAG tag) that has been included on the receptor for facile detection.

Kits

The present invention also provides therapeutic kits that are useful for carrying out the present invention. In one preferred embodiment, the kit provides a composition for *in vitro* administration of nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors. In another preferred embodiment, the kit provides nucleic acid molecules encoding constitutively active, hypersensitive, or nonfunctional receptors that can be administered to a mammal. Preferably, the nucleic acid molecule is a viral or non-viral vector encoding a constitutively active, hypersensitive, or nonfunctional receptor. In certain preferred embodiments, the viral or non-viral vector includes cell specific ligands useful for targeting specific cell-types in a mammal.

According to the present invention, the kits contain nucleic acid molecules that may be administered by any method available in the art. In one preferred embodiment, the kits include a first container means containing a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor, e.g., a viral or non-viral vector, in a pharmaceutically acceptable carrier. In one particularly preferred embodiment, the kits include an adenoviral vector encoding a constitutively active receptor, e.g., a constitutively active mu opioid receptor. Alternatively, if the means of delivery is a gene gun, the kit may include an aliquot of frozen or lyophilized nucleic acid encoding the constitutively active receptor. For gene gun delivery, the kit may also include a second container means that contains the small, inert, dense particles in dry powder form or suspended in 100% ethanol and, optionally, a third container means that contains the coating solution or the premixed, premeasured dry components of the coating solution. These container means can be made of glass, plastic, or foil and can be

a vial, bottle, pouch, tube, bag, etc. The kit may also contain written instructions, such as procedures for administering the composition, or analytical information, such as the amount of reagent (e.g. moles or mass of nucleic acid). The written information may be located on any of the first, second, and/or third container means, and/or a separate sheet
5 included, along with the first, second, and third container means, in a fourth container means. The fourth container means may be, e.g., a box or a bag and may contain the first, second, and third container means. It will be appreciated that this kit can be modified to include any reagent for administration described above, or known in the art.

10 All references cited herein are hereby incorporated by reference.

Examples

The present invention can be further understood through consideration of the following non-limiting examples.

15

Example 1: Constitutively Active Mu Opioid Receptor

This example describes the identification of a novel constitutively active rat mu opioid receptor and use of nucleic acids encoding this receptor in gene therapy.

20 *Identifying Regions of Homology in the Mu Opioid Receptor*

A database containing sequence information for known constitutively active Class A G protein-coupled receptors was generated by compiling available information from the prior art (see Fig. 1). The database was then used to identify key residues within Class A G protein-coupled receptors that are important for constitutive activity.

25 These highly conserved residues are illustrated in Fig 8. Of particular interest was the

Asn residue at position 150 of SEQ ID NO: 1 in transmembrane domain III, which is conserved between the rat mu opioid receptor, the bradykinin B2 receptor, and the angiotensin II AT1A receptor (see Fig. 8). The 'DRY' motif at position 164-166 of SEQ ID NO: 1 is conserved between the oxytocin receptor, the vasopressin-V2 receptor, the cholecystokinin-A (CCK-A) receptor, the melanocortin-4 (MC-4) receptor, and the α_{1B} adrenergic receptor (see Fig. 9). It is important to note that this general motif, although not necessarily consisting of the specific residues 'DRY' (an alternative is, e.g., 'ERY'), is conserved among all class A G protein-coupled receptors. In addition, the position corresponding to 13 residues N-terminal to the 'CWLP' motif is functionally conserved between the 1A adrenergic receptor, the α_{2C} adrenergic receptor, the β_2 adrenergic receptor, the CCK-B receptor, the platelet activating factor receptor, and the thyroid stimulating hormone receptor (see Fig. 11) in that mutation of the amino acid at position -13 in each of these receptors results in constitutive activity. "Functionally conserved" means that the same amino acids are not necessarily present, but mutations in homologous or surrounding positions can result in constitutive activity.

Generating Mutant Mu Opioid Receptors

Based on the homology between the mu opioid receptor, the bradykinin B2, and the angiotensin II AT1A receptors at the Asn residue at position 150 of SEQ ID NO: 1, we chose to generate a rat mu opioid receptor having a point mutation at this position. An Asn150Ala mutation was introduced into the rat mu opioid receptor using standard molecular biological techniques. This mutant gene was then subcloned into expression vector pcDNA1 (Sambrook et al. *supra*).

Assaying Mutant Mu Opioid Receptors for Constitutive Activity

Reagents & Solutions: The cell culture media used in the assays described below was Gibco BRL # 12100-046. This media was made according to manufacturer's recipe, pH adjusted to 7.2, filtered (0.22 micron pore), and supplemented with 1% Pen/Strep (Gibco #15140-122 ; 100% penicillin G 10,000 units/ml, and streptomycin 10,000 µg/ml) and 10% fetal bovine serum. Cell culture media lacking 10% fetal bovine serum was also generated. DNA used in the transfection experiments was purified and quantitated by measuring the absorbance at OD260. A LucLite Luciferase Assay Kit (Packard) was used to quantitate luciferase activity. Transfections were carried out using LipofectAMINE Reagent (Gibco #18324-012).

Constitutive activity of the Asn150Ala mutant rat mu opioid receptor was assessed using a luciferase assay. The rat mu opioid receptor is a G α i coupled receptor. Therefore we chose to use the Gq5i reporter system, described in detail above (Broach and Thorner, *supra*), which switches the signaling pathway from G α i to G α q for reliable positive readout. HEK293 cells were transfected with the reporter construct SRE-Luc, an expression vector containing nucleic acid encoding Gq5i (Broach and Thorner, *supra*), and an expression vector containing nucleic acid encoding either the wild-type or the Asn150Ala mutant rat mu opioid receptor. Basal and ligand-stimulated luciferase activity was measured. The ligand used in this assay was [D-Ala²-MePhe⁴, Gly-ol⁵]enkephalin] (DAMGO). As a negative control, HEK293 cells were transfected with pcDNA1 (empty vector DNA), SRE-Luc, and the expression vector containing nucleic acid encoding Gq5i (Broach and Thorner, *supra*).

The luciferase assay was carried out as follows. On day 1, HEK293 cells in a T75 flask were washed with 15 ml serum-free media (or PBS), trypsinized with 5 ml 0.05% trypsin-EDTA (Gibco #25300-062), incubated at 37°C for 3 minutes at which

time 6-7 ml complete HEK293 media (Gibco #12100-046) and 10% Fetal Bovine Serum (Intergen #1050-90) were added. Thereafter, cells were collected in 50 ml centrifuge tubes, pelleted at 800-900 rpm (RCF ~275), and resuspend in 20 ml complete media.

The cells were counted using a haemocytometer and diluted to 85,000 cells/ml in

5 complete media. Using a repeat pipettor or cell plater, 100 µl of cells were added to each well of a Primaria 96-well plate (Falcon #353872). Cells were then incubated at 37°C, 5% CO₂ until use at 48 hours.

On day 3, cells were transfected using LipofectAMINE™ according to the manufacturer's protocol (Gibco #18324-012, Rockville, MD).

10 On day 4, cells were stimulated as follows. Ligands for the receptor, either DAMGO or a non-peptide ligand (e.g., naloxone or naltrexone), were diluted to a desired concentration in serum-free media containing 0.15 mM PMSF (or other protease inhibitor(s)). The transfection media was then completely removed from cells and 50-100 µl stimulation media (i.e., media containing candidate ligands or the corresponding
15 ligand free solvent) was added to each well. The cells were incubated for the desired time (standard is overnight) at 37°C, 5% CO₂, although the optimal stimulation time may vary depending on the particular receptor used. The optimal incubation time may be determined systematically by testing a range of incubation times and determining which one yields the highest level of stimulation. For concomitant assessment of two ligands
20 (e.g., ligand induced inhibition of forskolin stimulated CRE activity) each stimulus is prepared at two times the desired final concentration and mixed in equal volumes prior to addition to cells.

On day 5, an assay for luciferase expression was carried out according to the manufacturer's instructions (Packard, Meridin, CT)

Results: Mu Opioid Receptor

5 Mutation of the Asn residue at position 150 of SEQ ID NO: 1 to Ala yielded a constitutively active rat mu opioid receptor. In Fig. 6 and Table 1, below, the results of the wild-type and Asn150Ala mutant rat mu opioid receptors are compared side by side. Shown in Fig. 6 are the basal and ligand-stimulated activities of the wild-type rat mu opioid receptor and the basal activity of the negative control vector (pcDNA 1 lacking
10 any encoded gene). The basal activity of the wild-type rat mu opioid receptor is exceeded by the basal activity of the negative control vector. There is a significant increase (approximately 6.5 fold) in basal activity of the Asn150Ala mutant mu opioid receptor, indicating that the mutant mu opioid receptor is constitutively active.

15

Table 1

<u>Receptor</u> <u>Activity</u>	<u>Average Basal Activity</u> (Light Emission)	<u>Average Ligand Stimulated</u> (Light Emission)
pcDNA 1 (SRE + Gq5i)	16,041	16,746
wild-type rat mu opioid receptor (SRE + Gq5i)	8,436	87,461
Asn150Ala rat mu opioid receptor (SRE + Gq5i)	*56,498	86,996

5 * 6.5-fold stimulation of basal level activity.

Gene Therapy Using Mu Opioid Receptor Nucleic Acid

In a preferred gene therapy approach, an adenoviral construct is generated encoding the constitutively active (Asn150Ala) rat mu opioid receptor (see Fig. 17).

- 10 The construct is next injected into the intrathecal space of rats. After 1-2 days, allowing for expression of the receptor in the rat spinal cord, tail flick experiments are carried out, as described, for example, in Pollack et al. (*Pharm. Res.* 17(6):749-53 (2000)). The tail flick response to radiant heat (the amount of time it takes for the rat to remove its tail from a heat source) determines the analgesic effect of the constitutively active mu opioid
- 15 receptor. Constitutively active mu opioid receptors that reduce the sensitivity of a rat tail to heat are considered useful gene therapy constructs.

In humans, gene therapeutic agents containing nucleic acids encoding the constitutively active Asn150Ala human or rat mu opioid receptor may be injected into a patient for treatment of pain. Expression and activity of the constitutively active mu opioid receptor is assessed using well known methods, as described herein (e.g.,
5 standard immunological assays). Preferably, the expression and activity of the constitutively active rat mu opioid receptor is first examined in cells *in vitro* that are of the same type of cell or are the same cells (e.g., taken from the *in vivo* site and cultured *in vitro*), as those of the *in vivo* site. The gene therapeutic agent encoding the constitutively active rat mu opioid receptor is then injected into a patient that is
10 experiencing pain, for example, the intrathecal space for treatment of back pain.

Example 2: Constitutively Active Melanocortin-4 Receptor

This example describes the identification of a constitutively active melanocortin-4 (MC-4) receptor and use of such nucleic acids in gene therapy.
15

Identifying Regions of Homology and Generating MC-4 Receptor Mutants

As shown in Fig. 9, the “DRY” motif is conserved between the Class A G protein-coupled, oxytocin, vasopressin-V-2, cholecystokinin-A (CCK-A), melanocortin-4 (MC-4), and α_{1B} adrenergic receptors (Fig. 9). Based on this homology,
20 plus precedent that substitution of aspartic acid within the DRY motif results in constitutively active oxytocin, vasopressin V-2, CCK-A, and α_{1B} receptors, we hypothesized that substitution of the D (Asp) residue at position 146 of MC-4 by a non-charged residue would yield a constitutively active receptor (the MC-4 sequence is available as Genbank Accession is L08603). An Asp146Met mutant MC-4 receptor
25 was generated using routine methods.

Assaying of Mutant MC-4 Receptors for Constitutive Activity

As demonstrated in Fig. 10, the reporter system assay was capable of detecting constitutive activity of the mutant Asp146Met MC-4 receptor. Briefly, HEK293 cells
5 were cotransfected, as described above, with an expression vector encoding either the wild-type MC-4 receptor or the Asp146Met mutant MC-4 receptor and the reporter construct, SMS-Luc. As a negative control, cells were transfected with SMS-Luc and pcDNA1. Basal and ligand (α MHS) induced activity of the negative control, the wild-type MC-4 receptor, and the Asp146Met mutant MC-4 receptor were measured using the
10 luciferase assay described above. The Asp146Met mutant MC-4 receptor mutant clearly exhibited a higher basal level activity than its wild-type counterpart.

Gene Therapy Using MC-4 Receptor Nucleic Acid

The MC-4 receptor is a G protein-coupled seven transmembrane receptor
15 expressed in the brain that has been implicated in a maturity onset obesity syndrome associated with hyperphagia, hyperinsulinemia, and hyperglycemia in mice (Huszar et al. *supra*). Specifically, chronic antagonism of the MC-4 receptor by the agouti polypeptide induces a novel signaling pathway that increases glucose tolerance and results in increased body weight. Agonists that activate this pathway through the MC-4
20 receptor have been shown to be useful in decreasing body weight. Thus, according to the invention, nucleic acids encoding constitutively active MC-4 receptors are administered to a mammal to decrease glucose tolerance for treatment of obesity related to hyperphagia, hyperinsulinemia, and hyperglycemia. Gene therapy agents including nucleic acids encoding constitutively active MC-4 receptors are generated using any art
25 available method and administered to the brain for treatment and/or management of

obesity.

Example 3: Constitutively Active β 2 Adrenergic Receptors

This example describes the identification of constitutively active
5 β 2 adrenergic receptors and use of such nucleic acids in gene therapy.

Identifying Regions of Homology and Generating Constitutively Active β 2 Adrenergic Receptor

As described in Samama et al. *J. Biol. Chem.* 268(7):4625-4636 (1993), a
10 constitutively active mutant of the β 2 adrenergic receptor was generated by replacing the C-terminal portion of the third intracellular loop of the β 2 adrenergic receptor with the homologous region of the 1B adrenergic receptor (Fig. 1, page 3). This conservative substitution led to agonist independent activation of the β 2 adrenergic receptor. In addition, the constitutively active receptor has an increased intrinsic affinity for β 2
15 adrenergic receptor agonists and partial agonists, as well as an increased potency, and are therefore also hypersensitive.

Gene Therapy Using β 2 adrenergic Receptor Nucleic Acid

Agonists to the β 2 adrenergic receptor have been widely used to treat asthma. In
20 fact, inhaled beta-adrenergic agonists are the most commonly used treatments for asthma today (Drazen et al., *Am. J. Respir. Care Critical Med.* 162(1):75-80 (2000)). In addition, polymorphisms in the gene encoding the β 2 adrenergic receptor have been identified and correlated with asthma severity (Holloway et al., *Clin. Exp. Allergy* 30(8):1097-103 (2000)). Thus, according to the present invention, constitutively active

β 2 adrenergic receptors are useful therapeutic agents in the treatment and prevention of asthma.

The constitutively active β 2 receptors, described above, are provided on page 3 of Fig. 1. Thus, for treatment of asthma, nucleic acids encoding a constitutively active β 2 adrenergic receptor are administered to the bronchial surface of a mammal, for example, *via* an inhaler. Gene therapy agents including nucleic acids encoding constitutively active β 2 adrenergic receptors are generated using any art available method and administered to surfaces of the respiratory system for treatment and/or management of asthma.

Example 4: Constitutively Active α 1 Adrenergic Receptors

This example describes the identification of constitutively active α 1 adrenergic receptors and the use of such nucleic acids in gene therapy.

Identification of Constitutively Active α 1 Adrenergic Receptors

As illustrated in Fig. 1, page 2, numerous α 1 adrenergic receptors have been identified that have constitutive activity. Indeed, nineteen different amino acid substitutions of the Ala at position 293 of the α 1 adrenergic receptor result in constitutive activity of the receptor (Kjelsberg et al., *J. Biol. Chem.* 267(3):1430-1433 (1992)). Additional constitutively active mutants of the α 1 adrenergic receptor include mutants of the DRY motif at the junction between transmembrane domain III and intracellular loop 2. These mutants include the Asp142Ala mutant (Scheer et al., *Mol. Pharm.* 57(2):219-231 (2000)) and the Arg143Lys mutant (Scheer et al., *Proc. Natl. Acad. Sci USA* 94(3):808-813 (1997)). Another constitutively active mutant of the α 1 adrenergic receptor is the Asn63Ala mutant (Scheer et al., *supra* (1997)). Mutation of

this conserved Asn63 residue located N-terminal to the DRY motif frequently leads to constitutive activity in a variety of other G-protein-coupled receptors (see Fig. 8). Other constitutively active $\alpha 1$ adrenergic receptors include the Cys128Phe mutant (in transmembrane domain III) (Perez et al., *Mol. Pharmacol.* 49(1):112-122 (1996)); the
5 Ala293Glu mutant (carboxyl end of IC3) (Perez et al., *supra*); and the Ala204Val mutant (transmembrane domain V) (Hwa et al., *Biochemistry* 36(3):633-639 (1997). Other mutants include those described in Allen et al. (*Proc. Natl. Acad. Sci. USA* 88(24):11354-11358 (1991) and shown in Fig. 1, page 2).

10 *Gene Therapy Using $\alpha 1$ Adrenergic Receptor Nucleic Acid*

Phenylephrine is a commonly used agonist of the $\alpha 1$ adrenergic receptor for the treatment of nasal congestion. Thus, according to the present invention, constitutively active $\alpha 1$ adrenergic receptors are useful treatments for nasal congestion. Nucleic acids encoding constitutively active $\alpha 1$ adrenergic receptors can be
15 administered, e.g., to the surfaces of nasal passages, e.g., *via* a nasal spray, as a nasal decongestant.

Example 5: Constitutively Active and Nonfunctional Angiotensin Receptors

This example describes the identification of a constitutively active angiotensin
20 receptor, as adopted from Groblewski et al. (*J. Biol. Chem.* 272:1822-1826 (1994)), and use of nucleic acids encoding a constitutively active and nonfunctional angiotensin receptor in gene therapy.

Identifying Regions of Homology and Generating

A constitutively active mutant of the AT1A angiotensin II receptor, a G protein-coupled receptor, was identified as described by Groblewski et al. (*J. Biol. Chem.* 272:1822-1826 (1994); Feng et al., *Biochemistry* 37(45):15791-15798 (1998); see also
5 Feng et al. *supra*). Briefly, a previous molecular modeling study by Joseph et al. (*J. Protein Chem.* 14:381-398 (1995)) predicted an interaction between Asn 111 in transmembrane domain III and Tyr 292 of transmembrane domain VII in a non-activated AT1A angiotensin II receptor. Joseph et al. (*supra*) further predicted that in the activated receptor, this interaction would be disrupted. Groblewski et al. (*supra*)
10 observed that the Asn 111 residue of the AT1A angiotensin II receptor is found at a homologous position in other peptide hormone receptors, including angiotensin 2 and *Xenopus* angiotensin, bradykinin, opioid, interleukin 8, and somatostatin receptor. In these receptors, mutation of the Asn 111 residue may yield constitutively active receptors. Furthermore, Groblewski et al. (*supra*) observed that mutation of Cys128
15 (Perez et al., *Mol. Pharmacol.* 49:112-122 (1996)) in the α -1B adrenergic receptor, which occupies a position homologous to that of Asn 111 in the AT1A angiotensin receptor, also induced constitutive activation. Assessment of constitutive activity in the corresponding AT1A receptor mutant was achieved by measuring and comparing the basal level of inositol phosphate production of the wild type and mutant angiotensin
20 receptors (see Groblewski et al., *supra* Figs. 2, 3, and 4, *supra*).

In summary, through mutational analysis of the AT1A angiotensin II receptor, Groblewski et al. showed that mutation of the Asn at position 111 to Ala resulted in a receptor with strong constitutive activity. It will be appreciated that additional constitutively active AT1A angiotensin II receptors are identified by repeating the steps
25 of identifying regions of homology, introducing mutations, and assaying for increased

basal activity.

Gene Therapy Using Angiotensin Receptor Nucleic Acid

There are three angiotensin receptor subtypes, the angiotensin receptor I, II, and
5 IV. The cardiovascular and other effects of the ligand angiotensin II are mediated by the
angiotensin I and II receptors, which are seven transmembrane glycoproteins with 30%
sequence similarity. The angiotensin I receptor plays a key role in cardiovascular
homeostasis, whereas the angiotensin II receptor contributes to blood pressure and renal
function. The function of the angiotensin IV receptor is unknown, but high levels of
10 angiotensin IV receptor are found in the brain and kidney. (See De Gasparo et al.,
Pharmacological Reviews 52:415-472 (2000)).

Based on the role of angiotensin I and II in blood pressure regulation,
specifically in increasing blood pressure (Sosa-Canache et al., *J. Human Hypertension*
Apr; 14 Suppl; 1:S40-6 (2000); Siragy et al. *Hypertension* 35(5):1074-1047) (2000);
15 Ackerman et al., *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 278(6):R1441-5 (2000)),
mutants of angiotensin I and/or II receptors are useful therapeutics for disorders
involving blood pressure, e.g., to raise or lower blood pressure. According to the
invention, administration of nucleic acids encoding mutant angiotensin I or II receptors
are used to raise or lower blood pressure, e.g., for treatment of hypertension or
20 hypotension. For example, for treatment of hypertension, e.g., to lower blood pressure,
a nucleic acid encoding a non functional angiotensin I or II receptor is selected. For
treatment of hypotension, e.g., to raise blood pressure, constitutively active angiotensin
receptor is selected. Treatment is achieved, for example, by injecting a nucleic acid
encoding the non functional or constitutively active into the heart of a patient with
25 hypertension or hypotension, respectively.

Example 6: Constitutively Active Pituitary Adenylate Cyclase Activating PolypeptideType I Receptor

This example describes the identification of a constitutively active pituitary
5 adenylate cyclase activating polypeptide receptor, as adopted from Cao et al. (*supra*),
and use of nucleic acids encoding a constitutively active pituitary adenylate cyclase
activating polypeptide receptor in gene therapy.

10 *Identifying Regions of Homology and Generating Constitutively Active Mutants of the
Pituitary Adenylate Cyclase Activating Polypeptide Receptor*

Pituitary adenylate cyclase activating polypeptide (PACAP) receptors belong to a
family of Class B G protein-coupled receptors. The receptors of this family all couple to
Gs or Gq to stimulate adenylate cyclase. Other peptide hormone receptors in this family
15 include receptors for secretin, glucagon, glucagon-like peptide 1, growth hormone
releasing hormone, gastric inhibitory peptide, parathyroid hormone, and calcitonin.

An analysis of amino acid sequence homology among the various receptors of
Class B G protein-coupled receptors was carried out by Cao et al. (*supra*). The
alignment revealed a highly conserved glutamic acid in the putative center of a second
20 intracellular loop of the PACAP receptor (Cao et al., Fig. 1, *supra*). Mutant receptors,
wherein the glutamic acid residue was altered, were assayed for constitutive activity.
Specifically, basal level cAMP production was measured in cells expressing wild type or
mutant PACAP receptors to identify constitutively active mutants (Cao et al. Fig. 4,
supra). All mutations introduced at this position yielded constitutively active PACAP
25 receptors (Cao et al. (*supra*)). Since the glutamic acid residue is highly conserved, this

position is a target for mutation and analysis for other Class B G protein-coupled receptors.

Gene Therapy Using PACAP Nucleic Acid

5 PACAP is a neuropeptide originally isolated from ovine hypothalamus tissue and is one of the most potent known stimulators of adenylate cyclase. PACAP functions as a hypophysiotropic hormone and as a neurotransmitter, neuromodulator, and neurotrophic factor in the central nervous system. In light of these activities, gene therapeutic agents including nucleic acids encoding the PACAP receptor are useful in the treatment of a
10 wide variety of biochemical and neurological conditions.

Example 7: Constitutively Active Parathyroid Hormone Receptor

This example describes the identification of a constitutively active parathyroid hormone receptor, as adopted in part from Schipani et al. (*New Engl. J. Med.*
15 335:(10)708-714 (1996)), and use of nucleic acids encoding a constitutively active parathyroid hormone receptor in gene therapy.

Generating Constitutively Active Parathyroid Hormone Receptor

The parathyroid hormone (PTH) receptor is a Class B G protein-coupled receptor
20 that couples independently to the adenylate cyclase-activating Gs protein and the PLC β -activating Gq protein. In osteoblasts and osteoblast precursors, the PTH receptor couples to Gs to activate the adenylate cyclase-cAMP dependent protein kinase mechanism and to Gq to activate the phospholipase C β (PLC β)-Ca²⁺/protein kinase C (PKC) second messenger signaling pathways (Whitfield et al., *TIPS* 16:382-386 (1995)).
25 Other members of this gene family, which are highly conserved, include the receptors

for calcitonin, secretin, growth hormone-releasing hormones, vasoactive intestinal polypeptide (types 1 and 2), gastric-inhibitory polypeptide, glucagon-like peptide 1, glucagon corticotropin-releasing factor, and the pituitary adenylate cyclase activating polypeptide (Jüppner et al. *Curr. Opin. Nephrol. Hypertens.* 3(4):371-378, Fig. 1, p 373
5 (1994)).

Two polymorphic constitutively active PTH receptors have been identified (Schipani et al. *supra*). Briefly, upon comparison to wild-type sequence isolated from healthy patients, mutations in the gene encoding the PTH receptor were identified in patients with Janen's metaphyseal chondrodysplasia, a rare form of short-limbed
10 dwarfism associated with hypercalcinemia and normal or low serum concentrations of PTH and PTH-related peptide (PTHrP). These mutations include a His223Arg mutation and a Thr410Pro missense mutation (Schipani et al. (Abstract) *supra*). In COS-7 cells expressing the mutant PTH receptors, basal cyclic AMP accumulation was four to six times higher than in cells expressing wild-type receptors (Schipani et al., see Fig. 4,
15 *supra*). Other constitutively active Class B receptors can be identified using the sequence alignment provided by Jüppner et al. (*supra*) when residues that are homologous to H225 and T410 in the PTH receptor are targeted for mutation. The cAMP accumulation assay described by Schipani et al. (*supra*) is then employed to assess the basal activity of the mutant and the wild-type Class B receptor to determine
20 whether the mutant receptor is constitutively active.

Gene Therapy Using PTH Receptor Nucleic Acid

The PTH receptor is known to trigger bone growth. Specifically, the PTH receptor triggers bone growth through cAMP-mediated production and secretion of
25 autocrine and paracrine factors, such as insulin-like growth factor 1 and insulin-like

growth factor-binding protein 5, which stimulate osteoblast precursor proliferation and production of bone constituents by mature osteoblasts (Whitfield et al. *supra*).

Administration of PTH has been used to treat osteoporosis, frequently in combination with a therapy that prevents further bone loss (Whitfield et al. *supra*). According to the present invention, nucleic acids encoding a constitutively active or nonfunctional (inhibitory) PTH receptor are administered to the osteoclasts or osteoblast precursors of a patient for treatment of osteoporosis.

For example, nucleic acids encoding a constitutively active PTH receptor are injected directly into a bone of a patient at the site in the bone that has significant bone loss. Alternatively, osteoclasts or osteoblast precursor cells are transduced or transfected *ex vivo* and the cells later transferred to the site of bone loss in a patient diagnosed with osteoporosis. Alternatively, the cells are administered on a scaffolding and placed in the site of bone loss (see, e.g., WO 09/425,079; WO 09/ 012, 603; WO 09/012,604; WO 09/409,760, incorporated herein by reference). In certain cases, it may be desirable to carry out the gene therapeutic treatment simultaneously with the administration of agents that inhibit bone loss, and such determination can be made by one skilled in the art. Of course, one skilled in the art will appreciate that the activity of the PTH receptor would have to be closely monitored, and possibly titrated, as described herein, due to the fact that a constitutively active form of the PTH receptor is associated with disease.

Example 8: Constitutively Active Estrogen Receptor

This example describes the identification of a constitutively active estrogen receptor, as adopted from Weis et al., *Molecular Endocrinology* 10(11):1388-1398 (1996) and White et al., *EMBO J.* 16:1427-1435 (1997), and use of nucleic acids encoding a constitutively active estrogen receptor in gene therapy.

Identifying Regions of Homology and Generating Constitutively Active Estrogen Receptors

The estrogen receptor α (ER α or ER β) is a member of the nuclear steroid
5 receptor superfamily that regulates the transcriptional activation of many important
genes. Constitutively active ER α s have been identified, as described in Weis et al.
(*supra*). Briefly, the role of Tyr 537 in the transcriptional response of the ER α was
examined based on the fact that this residue is located close to a region of the hormone-
binding domain previously shown to be important in hormone-dependent transcriptional
10 activity, and further because this amino acid has been proposed to be a tyrosine kinase
phosphorylation site important in the activity of the ER α (Weis et al. *supra*). It was
shown that two of the ER α mutants, Tyr537Ala and Tyr537Ser, displayed estrogen-
independent constitutive activity that was approximately 20% and 100% of the activity
of the wild-type receptor, respectively. A reporter assay system was used to measure the
15 ability of the wild-type and mutant ER α to activate transcription. Specifically, an
estrogen responsive construct was made that included two estrogen-response elements,
the pS2 gene promoter, and a chloramphenicol acetyl transferase (CAT) reporter gene
(Weis et al., *supra*). A similar mutation of residue 541 in ER α (substitution with an
amino acid with reduced hydrophobicity) also yielded a constitutively active ER (White
20 et al., *supra*).

In order to identify additional constitutively active ERs, nonconstitutively active
ER polypeptides are compared to other family member receptor polypeptides that are
constitutively active. Regions of amino acids sharing homology are identified and
targeted for mutation. These mutant ERs are then assessed using a reporter assay
25 system, such as the CAT reporter assay system described by Weis et al. (*supra*) (or

described herein) to determine whether they possess constitutive activity compared to their nonconstitutively active counterparts.

The above steps are exemplified by Tremblay et al. (*Canc. Res.* 58(5):877-81 (1998)). The amino acid sequences of ER α and ER β were compared and regions of
5 homology were identified between tyrosine 537 of ER α and tyrosine 443 of the nonconstitutively active ER β (Tremblay et al. *supra*). These residues are known to be important for constitutive activity. To test whether constitutive activity could be conferred to ER β , corresponding mutations were generated in the ER β protein at tyrosine 443 (Tyr443Phe, Tyr443Ser, and Tyr443Asn). The resulting ER β mutants
10 were introduced by transient transfection into COS-1 cells and basal transcriptional activity measured using a luciferase reporter assay system responsive to ER activation (Tremblay et al. *supra*). The Tyr443Ser and Tyr443Asn ER β mutants exhibited a basal level of transcriptional activity that equaled the ligand-stimulated level of transcriptional activity observed for the wild-type receptor (Tremblay et al. Fig. 1, *supra*). Thus,
15 constitutive activity was successfully transferred to ER β using systematic analysis.

Gene Therapy Using the Estrogen Receptor Nucleic Acid

It is well known that the amount of estrogen released by the ovaries decreases with the onset of menopause. Therefore, the symptoms of menopause are treated by
20 administration of nucleic acid encoding a constitutively active estrogen receptor to the organs of the female reproductive system, e.g., the uterus or ovaries (e.g., using tissue specific administration and/or tissue specific promoters). For example, nucleic acids encoding a constitutively active estrogen receptor (e.g., naked DNA or nucleic acid contained in a viral vector) are injected directly into the uterus. Assessment of

expression of the ER is carried out using standard immunological assays, as described herein. Of course, one skilled in the art will appreciate that the activity of the ER would have to be closely monitored, and possibly titrated, as described herein, due to the fact that a constitutively active form of the ER is associated with breast cancer ((Tremblay et
5 al., *supra*)).

Example 9: Hypersensitive Erythropoietin Receptor

This example illustrates use of a hypersensitive EPO receptor for treatment of anemia using gene therapy.

10

Identifying Regions of Homology and Generating Hypersensitive Erythropoietin Receptors

The EPO receptor is a single transmembrane receptor that is a member of the cytokine receptor family. Hypersensitive EPO receptors are identified by comparing the
15 amino acid sequences of family members of non-hypersensitive and hypersensitive receptors of the cytokine receptor family to identify regions of homology and target specific amino acid residues for mutation. Once identified, mutant EPO receptors are generated using standard molecular biological techniques, as described herein, and assayed for hypersensitivity.

20

One assay that can be employed in detecting a hypersensitive EPO receptor is an assay that monitors the Jak2/Stat5 signaling pathway. Upon activation of the EPO receptor, Jak2 associates with EPO receptor and undergoes autophosphorylation. The activated Jak2 subsequently phosphorylates both the EPO receptor and the transcription factor, Stat5. Activated Stat5 then translocates to the nucleus, recognizes a specific base
25 sequence within the promoter of its target gene, and activates transcription of that gene.

In light of these receptor-induced activities, screening mutant receptors for hypersensitivity is accomplished by assaying EPO receptor-dependent activation of Jak2 and Stat5 by immunoprecipitation and immunoblot analysis, as described in Watowich et al. (*Blood* 34:2530-2532 (1999)). This assay is carried out in cells expressing the mutant EPO receptor or the wild-type EPO receptor and the basal activities of these receptors compared. A mutant EPO receptor that exhibits an response to low doses of EPO (i.e., activation of Jak2 and Stat5) relative to cells expressing the wild-type EPO receptor, is identified as a hypersensitive EPO receptor.

10 *Gene Therapy Using Erythropoietin Receptor Nucleic Acid*

The EPO receptor is expressed almost exclusively on erythroid precursor cells and functions to control the development of red blood cells. Deficiencies in the transmission of the EPO receptor signaling cascade leads to clinically abnormal red blood cell production, and has been linked to a number of diseases including anemia.

15 Gene therapeutic agents including nucleic acids encoding hypersensitive EPO receptors are transfected into erythroid precursor cells *ex vivo* and administered to a patient for treatment of anemia (see, e.g., Sokolic et al. *supra*). For example, bone marrow cells are collected from a patient and transfected or transduced with nucleic acid encoding a hypersensitive EPO receptor (e.g., see Kauppinen et al. *Mol. Genet. Metab.* 20 65(1):10-7 (1998)). Expression of the transgene can be monitored using immunoblot analysis and other well known methods. The cells, expressing the hypersensitive EPO receptor, are then readministered to the patient and allowed to proliferate *in vivo*. Alternatively, DNA encoding a hypersensitive EPO receptor can be injected directly into a patient, e.g., intravenously.

25

Example 10: Constitutively Active Glucagon-like Peptide-1 Receptor

This example describes the use of nucleic acids encoding a constitutively active glucagon-like peptide-1 receptor in gene therapy.

The glucagon-like peptide-1 (GLP-1) receptor is a G protein-coupled receptor
5 (Graziano et al. (*Biochem. Biophys. Res. Commun.* 196(1):141-146 (1993)). The human and rat GLP-1 receptor genes have been cloned and compared and regions of conservation identified (Dillon et al., Fig. 1, *supra*). GLP-1 receptor is activated by GLP-1, a hormone secreted from the distal gut that stimulates basal and glucose-induced insulin secretion and proinsulin gene expression (Dillon et al., *supra*). GLP-1 is
10 associated with inhibition of upper gastrointestinal motility and involvement of the CNS (van Dijk et al., *Neuropeptides* 33(5):406-414 (1999)).

The involvement of the GLP-1 receptor in basal and glucose-induced insulin secretion and proinsulin gene expression is good evidence that nucleic acids encoding constitutively active GLP-1 receptors are useful in the treatment of diabetes. For
15 example, B cells defective in glucose-dependent insulin secretion and production are isolated from a patient, cultured in vitro, and transfected with nucleic acid encoding a constitutively active GLP-1 receptor (e.g., a retroviral vector containing the nucleic acid encoding a constitutively active GLP-1 receptor). The transduced cells are then injected back into the patient intravenously for treatment of diabetes (see e.g., Sokolic et al.,
20 *Blood* 87(1):42-50 (1996)).

Example 11: Constitutively Active and Nonfunctional Cholecystokinin-B/Gastrin Receptors (CCK-BR)

This example describes the identification of a constitutively active CCK-BR
25 receptor, as adopted from Beinborn et al. (*J. Biol. Chem.* 273(23): 14146-14151 (1998))

and Beinborn et al., *Gastroenterology* 110, (suppl.) A1059) (1996)), and use of nucleic acids encoding a constitutively active and nonfunctional CCK-BR in gene therapy.

Identifying Regions of Homology and Generating Mutant CCK-BR Receptors

5 Molecular characterization of the third intracellular loop of the human CCK-BR led to the identification of a point mutation (Leu325Glu) which results in constitutive CCK-BR activity (see, Beinborn et al. *supra* (1996)). Briefly, the strategy was based on the theory that domain swapping between related polypeptides with different second messenger couplings could yield receptors having increased basal activity. Segments of
10 4-5 amino acids were substituted in the third intracellular loop of the CCK-BR with corresponding sequences from the vasopressin 2 receptor, a protein with 30% amino acid identity to CCK-BR. However, these proteins are coupled to different signal transduction pathways. CCK-BR is coupled to phospholipase C activation, whereas the vasopressin 2 receptor is coupled to adenylyl cyclase as the predominant signal
15 transduction pathway (Beinborn et al., *supra* (1996)).

Assaying Mutant CCK-BR Receptors for Constitutive Activity

As described in Beinborn et al., recombinant receptors were transiently expressed in COS-7 cells and ligand affinities were assessed by ¹²⁵I CCK-8 competition
20 binding experiments. In addition, phospholipase C-mediated production of inositol phosphate was measured in the absence and in the presence of agonists. One of the block substitutions from the vasopressin 2 receptor, 250AHVSA, conferred agonist-independent constitutive activity when introduced into the corresponding region of the third intracellular loop of the CCK-BR. The mutant CCK-BR triggered a 10-fold higher
25 basal turnover of inositol phosphate compared to wild-type CCK-BR. Substitution of

253SA and even 253S alone within the same segment was sufficient to confer constitutive activity as well (Beinborn et al., (Abstract) *supra* (1996).)

Additional studies were carried out as described in Beinborn et al. (*supra* (1998)). In particular, the Leu325Glu CCK-BR mutant triggers constitutive production of inositol phosphates to levels exceeding wild-type CCK-BR (Beinborn et al., Fig. 1A *supra* (1998)). Briefly, the human wild-type CCK-BR and the constitutively active Leu325Glu CCK-BR mutant were transiently expressed in COS-7 cells. Control cells (“no receptor”) were transfected with the empty expression vector, pcDNA1. Cells were pre-labeled overnight with myo-[³H]inositol and then stimulated with ligand for 30 to 60 minutes in the presence of 10 mM LiCl. The constitutively active CCK-BR mutant is clearly distinguished from the wild-type receptor by its ability to trigger inositol phosphate production in the absence of agonist.

In addition to these studies, we performed luciferase assays to measure the constitutive activity of the Leu325Glu CCK-BR mutant. HEK293 cells were transfected (as described above) with SMS-Luc and an expression vector encoding any one of pcDNA1, wild-type CCK-BR, or Leu325Glu CCK-BR. As demonstrated in the left panel of Fig. 3, the Leu325Glu CCK-BR mutant has increased basal level activity compared to the wild-type CCK-BR.

20 *Gene Therapy Using CCK-BR Nucleic Acid*

CCK-BR is a G protein-coupled receptor that has been implicated in modulating memory, anxiety, and pain perception, as well as in regulating gastrointestinal mucosal growth and secretion (Beinborn et al. *supra* (1998)). Thus, gene therapy treatment with nucleic acids encoding a constitutively active CCK-BR is applicable to the treatment of a wide range of diseases. These conditions may be treated with agonists or antagonists

to achieve a desired outcome. For example, increasing memory is generally be treated with an agonist to the CCK-BR receptor, whereas the conditions of anxiety, pain perception, and gastrointestinal mucosal growth and secretion are generally treated with antagonists of the CCK-BR receptor.

5 This knowledge can be applied to determine the type of receptor administered to obtain the desired outcome. For example, since treatment of memory loss generally requires an agonist, nucleic acids encoding a constitutively active CCK-BR are administered to the brain for treatment of memory loss. Alternatively, since antagonists are generally administered for treatment involving anxiety, pain perception, and
10 gastrointestinal mucosal growth and secretion, a nonfunctional (i.e., a dominant negative CCK-BR receptor) may be administered for treatment of these conditions, e.g., to the nervous system for treatment of anxiety, to a site where a mammal is experiencing pain for pain management, or to the gastrointestinal tract for treatment of gastrointestinal disorders, respectively.

15 Nucleic acids encoding a constitutively active CCK-BR are generated using any art available method and administered to a mammal for the treatment of a disease or disorder, as described above.

 In one particular example, a nucleic acid encoding CCK-BR receptor having a point mutation that generates a receptor that displays normal ligand binding, but does
20 not transmit a ligand induced signal issued as a gene therapeutic agent. Specifically, a Val1331Glu mutation in the CCK-BR receptor yields a hyposensitive receptor with little or no stimulation of inositol phosphate production, although the binding of the ligand to the receptor is normal (see Fig. 16). This nonfunctional receptor acts as a sink for endogenous ligand and effectively lowers the endogenous ligand concentration while
25 blocking transmission of the ligand induced signal. In one gene therapeutic protocol,

nucleic acid encoding this nonfunctional receptor is administered to the stomach to act as a sink for the gastrin ligand and thereby diminish gastrin-dependent acid secretion. Such administration can be used to treat peptic ulcer disease.

5 Example 12: Nonfunctional Bradykinin Receptor

This example describes use of nucleic acids encoding a nonfunctional bradykinin receptor in gene therapy.

Gene Therapy Using Nucleic Acid Encoding the Bradykinin B2 Receptor

10 The bradykinin B1 and B2 receptors are members of a family of G protein-coupled receptors that respond to kinins, a family of biologically active peptides that produce a number of biological effects, including activation of sensory pain fibers, smooth muscle contraction, endothelium-dependent vasodilation, and plasma extravasation (Marie et al. *supra* (1999)). In addition, the bradykinin B2 receptor has
15 been implicated in hypothyroidism (Savoie et al., *Am. J. Physiol.*, 255(4 Pt. 1):E411-5 (1988)).

Given the number of diseases and conditions with which the bradykinin B2 receptor has been implicated, a wide variety of gene therapy treatments using nucleic acids encoding mutant bradykinin B2 receptors or other kinin receptors, can be
20 envisioned. As but one example, since the bradykinin B2 receptor activates sensory pain fibers, a nucleic acid encoding a nonfunctional bradykinin B2 receptor is administered for the treatment of pain. Bradykinin B2 gene therapy agents are generated using any art available method and administered to a mammal for treatment of disease, as described above.

25

Example 13: Nonfunctional CCR-3 Receptors

The CC chemokine (CCR-3) receptor is a seven-transmembrane-spanning G protein-coupled receptor expressed on thymocytes that plays a major role in the recruitment of inflammatory cells in an allergic response. Specifically, the CCR-3 receptor binds the polypeptide eotaxin to effect the regulation of eosinophil trafficking. Eosinophils are important players in the asthmatic response. Antagonists that inhibit this pathway through the CCR-3 receptor are useful therapeutic agents in the treatment and prevention of asthma. Thus, gene therapy agents that include nonfunctional receptors are preferred agents for treatment of asthma. Nonfunctional mutants of the CCR-3 receptor may be generated by referring to a database of conserved G protein-coupled receptors having mutations that make the receptors nonfunctional and mutating the CCR-3 receptor at homologous positions.

For treatment of asthma, nucleic acids encoding a nonfunctional CCR-3 receptor are administered to the bronchial surface of a mammal, for example, *via* an inhaler. Gene therapy agents including nucleic acids encoding nonfunctional CCR-3 receptors are generated using any art available method and administered to the brain for treatment and/or management of obesity.

Example 14: Constitutively Active Dopamine Receptors

This example describes the use of nucleic acids encoding constitutively active dopamine receptors in gene therapy.

Mammalian dopamine receptors are seven transmembrane domain G protein-coupled proteins that fall into the class A or rhodopsin family based on conservation of amino acid sequence. Dopamine receptors can be further divided into two major types, D1-like and D2-like. These receptor groups are distinguished based on gene structure,

signal transduction pathways, and sensitivity to class specific agonist and antagonist drugs (Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999); Missale et al., *Physiol. Rev.* 78:189-225 (1998); Vallone et al., *Neurosci. Biobehav. Rev.* 24:125-132 (2000). The D1-like receptors include the D1 and D5 subtypes. These receptors are encoded by a single exon and signal primarily through Gs mediated activation of adenylate cyclase. The D2-like receptors include the D2, D3, and D4 subtypes. Each of the D2-like receptors is encoded by multiple exons offering the potential for alternatively spliced variants to exist. Dopamine-mediated signaling through the D2-like receptors is primarily through Gi/o induced inhibition of adenylate cyclase and modulation of ion channels.

The predominant dopamine receptors found in the striatum are the D1 and D2 subtypes (Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999). Expression has been shown by in situ hybridization, immunohistochemistry, and receptor autoradiography. Although it is agreed that the D1 and D2 receptors are highly expressed in striatum, the degree to which there is coexpression of D1 and D2 receptors within individual striatal neurons remains controversial (Missale et al., *Physiol. Rev.* 78:189-225 (1998); Surmeier et al., *J. Neurosci.* 16:6579-6591 (1996); Aizman et al., *Nat. Neurosci.* 3:226-230 (2000). Many studies have suggested that D1 receptors are expressed on dynorphin/substance P neurons whereas D2 receptors appear preferentially expressed on enkephalin-producing cells. Others, using confocal microscopy and functional readouts (e.g. sodium channel activation) suggest there is coexpression of both the D1 and D2 receptors in many, if not all, striatal neurons.

It is quite likely that both striatal D1 and D2 receptors modulate locomotor function, and both are therefore useful targets for the development of therapeutics for Parkinson's disease (PD). Parkinson's disease affects about 1% of adults over the age of

60. The full clinical manifestations include bradykinesia, rigidity, tremor, and gait abnormalities. The disease results from degeneration of the dopaminergic nigrostriatal pathway. The trigger for the degenerative process in most cases remains unknown. A minority of cases results from genetic abnormalities (e.g. mutation in the alpha synuclein or the Parkin gene) (Rohan de Silva et al., *Current Opinion in Genetics & Development* 10:292-298 (2000). With the gradual loss of dopaminergic neurons in the substantia nigra, there is progressive damage to the axonal projections that innervate the striatum. The loss of nigrostriatal dopaminergic neurons leads to a decrease in dopamine mediated striatal signaling (Rohan de Silva et al., *Current Opinion in Genetics & Development* 10:292-298 (2000); Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999); Missale et al., *Physiol. Rev.* 78:189-225 (1998). In humans as well as in rodents and nonhuman primates, toxins that destroy dopaminergic neurons (e.g. MPTP, 6-OH dopamine) result in the acute onset of Parkinsonian symptoms. Use of these toxins has enabled the development of animal models of PD.

15 Therapeutic strategies for PD are aimed at restoring dopaminergic activity in the striatum. One means to achieve this is to increase central dopamine levels. Levo-dopa (L-dopa), the precursor of dopamine has been the primary drug used for this purpose. When administered peripherally, L-dopa (unlike dopamine) crosses the blood brain barrier and is then enzymatically converted to dopamine. In patients with Parkinson's disease, loss of nigrostriatal presynaptic cells leads to dopamine depletion despite intact striatal postsynaptic neurons. With disease progression pharmacotherapy is ultimately insufficient to restore normal striatal dopaminergic signaling. In addition, L-dopa administration to patients with advanced PD results in dyskinesias and periods of marked fluctuation in motor activity ('on-off effect'). Alleviation of these side effects has been a major challenge in the treatment of PD and has prompted a search for

therapeutic strategies that can provide a sustained level of dopaminergic signaling.

One approach to restore striatal dopaminergic activity and at the same time to potentially avoid the consequences of long term L-dopa administration is through the introduction of constitutively active dopamine receptors. Accumulating evidence

5 supports the idea that the D1 and D2 receptors act synergistically in mediating motor function (Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999); Missale et al., *Physiol. Rev.* 78:189-225 (1998); Paul et al., *J. Neurosci.* 12:3729-3742 (1992); Usiello et al., *Nature* 408:199-203 (2000). Therefore, constitutively active dopamine receptors may be administered alone as well as in combination. In addition, these constitutively active
10 dopamine receptors may be administered in conjunction with any other Parkinson's therapeutic including, without limitation, L-dopa, dopamine synthetic enzymes (for example, tyrosine hydroxylase or aromatic amino-dopacarboxylase), neuronal growth factors (for example, glial cell line-derived neurotrophic factor (GDNF)), or dopamine receptor agonists.

15 Expression of constitutively active dopamine receptors in the striatum provide a number of advantages for Parkinson's disease therapy. First, activated rather than wild type receptors are expressed. With constitutively active receptors, mutation-induced signaling persists even after dopamine depletion (as typically occurs with progression of Parkinson's disease). In addition, the use of constitutively active receptors as a therapy
20 also provides a means to attain a stable level of striatal signaling and thus circumvent one of the major disadvantages of classical L-dopa treatment, the fluctuating motor responses and the dyskinesias which occur in patients with advanced disease. Moreover, the D2L and D1 receptors may be expressed individually or in combination. Ample evidence suggests D1 and the D2L receptors act synergistically in stimulating motor
25 function (Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999); Missale et al., *Physiol.*

Rev. 78:189-225 (1998); Paul et al., *J. Neurosci.* 12:3729-3742 (1992); Usiello et al.,
Nature 408:199-203 (2000). In addition, recombinant adeno-associated virus (rAAV)
may be utilized rather than adenovirus as a gene therapy vector. rAAV is less
immunogenic than adenovirus and therefore persists for a considerably longer period of
5 time. Adenovirus constructs used previously (Ikari et al., *Brain Res. Mol. Brain Res.*
34:315-320 (1995); Ingram et al., *Mech. Ageing Dev.* 116:77-93 (2000)) began to
disappear 3-5 days after infection of the CNS. It is estimated that expression of rAAV
should last a minimum of 60 days (Bjorklund et al., *Brain Res.* 886:82-98 (2000).

10 *Constitutively Active Dopamine Receptors*

It is well established that the D1 receptor is coupled to Gs mediated activation of
adenylate cyclase, which in turn leads to elevation in cellular cAMP. D1R activation of
Gs was confirmed using both the luciferase assay described herein as well as a cAMP
radioimmunoassay. In contrast, D2 receptors (both long and short isoforms) are linked
15 to G_{i/o} coupled pathways. Activation of the D2 receptor leads to alpha subunit-mediated
inhibition of adenylate cyclase with a resultant decrease in cAMP (Emilien et al.,
Pharmacol. Ther. 84:133-156 (1999); Missale et al., *Physiol. Rev.* 78:189-225 (1998);
Vallone et al., *Neurosci. Biobehav. Rev.* 24:125-132 (2000). Activation of G_{i/o} was also
confirmed for the D2L and D2S receptors by expressing these receptors in HEK293 cells
20 and measuring activity with the Gq5i/ SRE luciferase reporter gene assay described
above.

In addition to these major pathways, there is evidence that second messenger
signaling linked to dopamine receptors includes certain other pathways that are highly
cell type specific (Missale et al., *Physiol. Rev.* 78:189-225 (1998); Jiang et al., *Proc.*
25 *Natl. Acad. Sci. USA* 98:3577-3582 (2001). Stimulation of dopamine receptors

potentially results in activation of potassium channels, inhibition of calcium currents, and activation of mitogen activated protein kinase. In addition, in certain cellular milieus, both the D1 and D2 receptors have been shown to activate phospholipase C, leading to phosphatidylinositol-mediated increases in intracellular calcium.

5 Assays based on any of the above signaling pathways may be used to identify or confirm constitutive activity for a dopamine receptor simply by looking for increased activity relative to a wild-type control receptor, as described herein.

 In particular, to isolate constitutive dopamine receptors, the relevant dopamine receptor cDNAs (e.g., D1, D2S, or D2L) are obtained or generated by PCR and
10 preferably cloned into the expression vector, pcDNA1.1. Single stranded uracil template is then preferably used as the template for site-specific mutagenesis by standard techniques.

 Potential amino acid targets for mutagenesis include two D1R (Cho et al., *Mol. Pharmacol.* 50:1338-1345 (1996); Charpentier et al., *J. Biol. Chem.* 271:28071-28076
15 (1996)) and one D2R (Wilson et al., *J. Neurochem.* 77:493-504 (2001)) point mutations reported to confer ligand independent signaling to the respective receptor. These may be generated as previously described (Beinborn et al., *Nature* 362:348-350 (1993); Kopin et al., *J. Biol. Chem.* 270:5019-5023 (1995)) and assessed by any of the assays described herein. These mutations, as characterized in the literature, confer only a minimal level
20 of constitutive activity. Ideally, a basal level of signaling can be achieved which approximates >50% of the dopamine-stimulated maximum activity. To enhance activity, serial amino acid substitutions may be introduced in candidate locations. This approach produces receptors with a wide range of basal signaling including ones with marked constitutive activity (Kjelsberg et al., *J. Biol. Chem.* 267:1430-1433 (1992);
25 Scheer et al., *Proc. Natl. Acad. Sci. USA* 94:808-813 (1997). An additional strategy,

which may be used, is to introduce combinations of weakly activating mutations in an attempt to further increase basal signaling. Specific mutations that may be introduced into the dopamine 1 receptor include replacement in intracellular loop 3 of the amino acid -20 from the "CWLP" sequence with either an I, E, or S, or replacement in
5 transmembrane region 6 of the L in the "CWLP" sequence with either an A, V, K, or E. Specific mutations that may be introduced into the dopamine 2 receptor include replacement in intracellular loop 3 of the amino acid -13 from the "CWLP" sequence with either an E, K, R, A, S, or C.

In addition, the deduced amino acid sequence of the D1 and D2 receptors include
10 "hotspots" relative to conserved signature motifs (e.g., DRY) in other class A GPCRs. Additional mutants may be constructed based on this hotspot in intracellular loop II. For example, the D in the "DRY" sequence may be replaced with either an M, T, V, I, or A, or the R may be replaced with either an A or K. As above, these receptors are generated by site-specific mutagenesis, sequenced for confirmation of the amino acid alteration,
15 and screened for constitutive activity. Agonist induced signaling is included as a positive control; this also enables normalization/comparison of elevations in basal signaling (i.e. agonist induced signaling = 100%).

In the alternative, random mutations may be introduced into a limited domain of the dopamine receptor of interest; mutant receptors are then screened for ligand
20 independent signaling. Preferred domains for such mutagenesis include the amino and carboxy ends of the third intracellular loop as well as the sixth transmembrane domain.

As described above, mutants are screened with a series of luciferase reporter gene assays to detect Gs, Gi/o, and Gq mediated signaling. To confirm that Gs coupled mutants are constitutively active, basal cAMP production may be assessed using the
25 flashplate assay (NEN). Agonist stimulated levels of cAMP or comparison with a

known constitutively active Gs coupled receptor mutant (e.g., PTH receptor T410P) may be included as positive controls.

For dopamine receptor mutants that trigger Gi/o mediated signaling, confirmation of constitutive activity may be carried out in forskolin-stimulated cells.

- 5 Basal signaling in forskolin treated cells expressing the wild type vs. constitutively active mutant are compared. The elevation in cAMP (or corresponding luciferase activity) resulting after forskolin stimulation should be decreased to a greater extent in cells expressing the constitutively active (vs. WT) receptors.

- If the luciferase results suggest that constitutively active mutants are Gq coupled
10 (i.e., activate the SRE-luciferase to a greater extent than the corresponding wild type receptor), follow up confirmatory studies may be used to assess the basal (i.e., ligand independent) level of receptor mediated production of inositol phosphates. Agonist stimulated levels of inositol phosphate production or comparison with a known constitutively active Gq coupled receptor mutant (e.g., CCK-2R, L325E) may be
15 included as positive controls.

- As a final test of constitutive activity, cells expressing constitutively active mutants may be treated with inverse agonists. Known inverse agonists for both the D1 and D2 receptors include (+)-butaclamol, haloperidol, and clozapine (Wilson et al., *J. Neurochem.* 77:493-504 (2001); Cai et al., *Mol. Pharmacol.* 56:989-996 (1999). These
20 compounds inhibit ligand-independent signaling, and thus confirm mutation induced receptor activation.

- To confirm the efficacy of constitutively active dopamine receptors, *in vivo* function of such receptors in adult rats may also be characterized. Specifically, recombinant adeno-associated viral constructs encoding the constitutively active
25 receptors are injected unilaterally into rat striatum and 'circling behavior' quantified as

an index of mutant receptor efficacy. It has previously been established that asymmetric striatal dopamine receptor mediated signaling results in circling behavior, away from the side with increased receptor mediated signaling. In animal models with unilateral overexpression of wild type D2 receptors resulting from infection with the
5 corresponding adenoviral construct (Ikari et al., *Brain Res. Mol. Brain Res.* 34:315-320 (1995); Ingram et al., *Exp. Gerontol.* 33:793-804 (1998), peripheral administration of apomorphine (a dopamine receptor agonist) results in circling. Asymmetry in striatal dopamine 2 receptor expression has also been achieved by unilateral administration of 6-hydroxydopamine (6-OHDA), a neurotoxin that destroys nigrostriatal neurons and leads
10 to an upregulation of D2 receptors on the 6-OHDA injected side (Sibley, *Annu. Rev. Pharmacol. Toxicol.* 39:313-341 (1999); Ozawa et al., *J. Neural Transm. Suppl.* 58:181-191 (2000); Ungerstedt et al., *Brain Res.* 24:485-493 (1970); Mendez et al., *J. Neurosurg* 42:166-173 (1975). Again, peripherally administered apomorphine results in circling behavior away from the side of increased receptor activity.

15 Because unilateral expression of constitutively active mutant dopamine receptors in the striatum is expected to result in asymmetric receptor mediated signaling, overexpression of such receptors should induce circling behavior independent of agonist stimulation. Without being bound to a particular theory (Emilien et al., *Pharmacol. Ther.* 84:133-156 (1999); Missale et al., *Physiol. Rev.* 78:189-225 (1998); Paul et al., *J. Neurosci.* 12:3729-3742 (1992); Uziel et al., *Nature* 408:199-203 (2000); Sibley,
20 *Annu. Rev. Pharmacol. Toxicol.* 39:313-341 (1999), we believe the best candidate receptors to induce locomotor activity are the constitutively active D2L receptors, expressed either alone or in combination with constitutively active D1 receptors.

Dopamine Receptor Constructs

Complementary DNAs encoding each of the wild type and mutant D1, D2L, and D2S receptors are cloned into a rAAV transfer plasmid. This construct includes a
5 neuron specific enolase promoter and an internal ribosomal entry site driving receptor and, for animal tests, green fluorescent protein expression bicistronically (Klein et al., *Brain Res.* 847:314-320 (1999). Co-expression of green fluorescent protein allows rapid assessment of transduction efficiency. Similar rAAV constructs have been demonstrated to give high-level striatal expression. Any rAAV construct may be used in the methods
10 of the invention, for example, those rAAV constructs available from the University of Florida's Gene Therapy Center (Vector Core Facility) (see, for example, <http://www.gtc.ufl.edu/gtc-home.htm>; <http://www.gtc.ufl.edu/gtc-vraav.htm>).

Recombinant AAV provides a number of advantages (Ozawa et al., *J. Neural. Transm. Suppl.* 58:181-191 (2000); Bjorklund et al., *Brain Res.* 886:82-98 (2000);
15 Mandel et al., *Experimental Neurology* 159:47-64 (1999). First, the wild type vector lacks any disease association. Second, rAAV can be used with transcripts up to 5 Kb; dopamine receptor transcripts are ~1.5-2 Kb. Third, transgenes integrate into the host genome resulting in stable expression. Fourth, immune response to rAAV is markedly diminished since 96% of the viral genome has been removed; only genes for packaging
20 and integration remain intact. Fifth, rAAV can transduce both non-dividing and dividing cells. Sixth, well-documented, high efficiency transduction occurs in striatal neurons. And, seventh, high-level expression is achieved for at least 2-6 months post infection.

For each dopamine receptor, virus encoding wild type and a constitutively active mutant (ideally with 50-100% activity, relative to the dopamine induced maximum, as assessed by in vitro assays) are generated. An empty rAAV vector is utilized as an additional negative control.

5 As each preparation of rAAV is completed, constructs are tested in HEK293 cells to ensure adequate receptor expression as well as confirmation of basal receptor mediated signaling. After rAAV infection, receptor densities are determined using homologous competition binding experiments with tritiated SCH 23390 or tritiated spiperone, selective radioligands for the D1 or D2 receptor, respectively Ozawa et al., *J. Neural. Transm. Suppl.* 58:181-191 (2000); Ingram et al., *Mech. Ageing Dev.* 116:77-93
10 (2000). Constitutive activity is verified with the appropriate luciferase reporter assay, SMS-luciferase for the D1 receptor and SRE-luciferase / Gq5i for the D2 receptor.

Constructs (rAAV encoding a constitutively active mutant receptor, a wild type receptor, or no receptor) may then be tested in male Sprague-Dawley rats (250-300 g) of
15 comparable age for effects on circling behavior as described above. Ten animals will comprise each group. In these tests, each rat receives a single unilateral injection of rAAV, 4 μ l of a $\sim 10^{12}$ particles per ml stock, into the dorsolateral striatum (DLS). This dose of virus is similar to ones used in earlier studies that successfully targeted the striatum (Ozawa et al., *J. Neural. Transm. Suppl.* 58:181-191 (2000); Bjorklund et al.,
20 *Brain Res.* 886:82-98 (2000); Klein et al., *Brain Res.* 847:314-320 (1999). A rAAV construct encoding GFP may be used to confirm that the striatal coordinates for injection (as per the Paxinos and Watson, *Stereotaxic Atlas of the Rat Brain*, 1998) target the DLS. In these animals it may also be determined whether and to what extent there is expression of GFP outside the targeted region; appropriate adjustments in dose, number
25 of injections, and/or coordinates may be made based on these measurements.

Circling behavior in ten adult male rats is compared with equal numbers of controls. Animals are evaluated every other day for the onset of circling behavior by placing rats in a circular chamber (diameter=36 cm.) and monitoring behavior. Circling is recorded and quantified using the Ethovision video monitoring system (Noldus Information Technologies, Sterling, VA). If no spontaneous circling behavior is evident after 5 weeks, animals are evaluated after peripheral administration of apomorphine, a dopamine receptor agonist. The 5-week interval allows ample time to achieve a stable level of receptor expression levels (Ozawa et al., *J. Neural. Transm. Suppl.* 58:181-191 (2000); Bjorklund et al., *Brain Res.* 886:82-98 (2000). Apomorphine-induced circling away from the side of the rAAV injection indicates that the viral construct induced receptor overexpression/ asymmetry. At the same time, a lack of spontaneous circling in the absence of drug treatment suggests that the level of receptor expression and/or basal activity was not sufficient to induce spontaneous circling. In this case, expression levels may be increased by utilizing a higher dose of the injected rAAV construct and/or by widening the striatal field injected (Ozawa et al., *J. Neural. Transm. Suppl.* 58:181-191 (2000); Bjorklund et al., *Brain Res.* 886:82-98 (2000). As detailed below, the level of receptor expression is quantified by receptor autoradiography to monitor how alterations in dose/ injection pattern influence striatal receptor density. Alternatively, the rAAV constructs may be further optimized by identifying additional point mutations that confer a greater degree of constitutive activity, as described above.

Once results are known with each construct individually, a combination of the constitutively active D2L and D1 rAAV constructs may be injected in parallel in equal amounts. A combination of corresponding wild type constructs are used as a control.

In addition to enhancing locomotor behavior, excess receptor activity might result in abnormal movements including writhing and/or tremors. In this case, a lower dose of the injected rAAV construct(s) is used and/or the striatal field injected is narrowed. Alternatively, the relevant rAAV construct(s) could be made with a less
5 constitutively active receptor mutant.

Receptor expression is assessed in all rats (i.e., those that circle as well as those that do not) after completion of circling behavior studies. Rats are anesthetized with pentobarbital. The animals are then perfused transcardially with phosphate buffered saline followed by 4% paraformaldehyde w/sucrose. Brains are removed, frozen, and
10 cut into transverse sections (20 microns) that extend through the striatum bilaterally. Since the rAAV constructs used in the animal tests encode green fluorescent protein (GFP) in parallel with the receptors, GFP expression provides a rapid index of protein expression. The brain sections also allow assessment of (i) tissue damage, (ii) accuracy of cannula placement, and (iii) dorsolateral striatum specific expression. To quantify
15 striatal receptor expression, frozen brain sections are assessed using receptor autoradiography with subtype selective radioligands, tritiated spiperone for D2 receptors and tritiated SCH 23390 for D1 receptors (Sibley, D.R., *Annu. Rev. Pharmacol. Toxicol.* 39:313-341 (1999); Xu et al., *Cell* 79:729-742 (1994); Ingram et al., *Mech. Ageing Dev.* 116:77-93 (2000). The autoradiographic signals are measured using the Alpha Innotech
20 Corp. ChemImager 4400 densitometer. Parallel controls include animals injected with an empty rAAV as well as with rAAV encoding wild type receptors.

Constitutively active dopamine receptors may also be evaluated in other animal models of PD. rAAV constructs which result in spontaneous circling when expressed either alone (e.g. D2L CAM) or in combination (e.g. D2L-CAM + D1-CAM) may be
25 further evaluated using the 6 hydroxydopamine (6-OHDA) induced rat model of

Parkinson's disease published by Diaz et al. (Rodriguez Diaz et al., *Behav. Brain Res.* 122:79-92 (2001); Breese, G.R., et al., *Br. J. Pharmacol.* 42:88-99 (1971); Rodriguez et al., *Exp. Neurol.* 169:163-181 (2001). In this model, 6-OHDA dose dependent decrease in spontaneous locomotor activity has been demonstrated with an accompanying
5 increase in chewing behavior and catalepsy. Constitutively active receptors (vs. wild type receptors vs. empty rAAV construct) may be tested to determine whether their bilateral expression in the striatum protects against these 6-OHDA induced behavioral abnormalities. The protective effects of the constructs can be quantified relative to the dose of 6-OHDA administered.

10

Gene Therapy Using Constitutively Active Dopamine Receptor Nucleic Acid

Given the role of dopamine receptors in modulating locomotor function, constitutively active receptors provide a novel and useful approach to treating neurological disorders, such as Parkinson's disease. In this approach, nucleic acids
15 encoding constitutively active dopamine receptors (for example, constitutively active dopamine 1 and/or dopamine 2 receptors) are administered, alone or in combination, to a mammal to increase dopaminergic activity. Preferably, these nucleic acids are delivered using recombinant adeno-associated viral vectors, and administration is preferably to the brain (for example, to the striatum).

20

In addition, as noted above, constitutively active dopamine receptors may be administered in conjunction with any other Parkinson's therapeutic including, without limitation, L-dopa, dopamine synthetic enzymes (for example, tyrosine hydroxylase or aromatic amino-dopacarboxylase), neuronal growth factors, or dopamine receptor agonists. Co-administration with the neuronal growth factor, glial cell line-derived
25 neurotrophic factor (GDNF), represents a preferred co-administration approach.

Other Embodiments

The present invention provides therapeutic compositions that include nucleic acids encoding constitutively active, hypersensitive, or nonfunctional receptors and methods for delivering the therapeutic compositions to a mammal in need of treatment that may replace current agonist drug therapy. The skilled artisan will appreciate that any means of delivering the nucleic acid compositions to a cell, tissue, or mammal may be used in the present invention. One of ordinary skill in the art would also appreciate that the present invention is not limited to applications involving use of the G protein-coupled receptors, but may be extended to other constitutively active, hypersensitive, or nonfunctional receptors.

From the foregoing description, it will be apparent that variations and modifications may be made to the invention described herein to adopt it to various usages and conditions. Such embodiments are also within the scope of the following claims.

All publications mentioned in this specification are hereby incorporated by reference to the same extent as if each independent publication or patent application was specifically and individually indicated to be incorporated by reference.

What is claimed is:

Claims

1. A method of treating or preventing a disorder in a mammal or improving the health of a mammal, said method comprising administering to said mammal a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor in an amount sufficient to treat or prevent said disorder or improve the health of said mammal.

2. The method of claim 1, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a single transmembrane domain receptor.

10

3. The method of claim 1, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a nuclear receptor.

4. The method of claim 3, wherein said nuclear receptor is a steroid hormone receptor.

15

5. The method of claim 1, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a constitutively active G protein-coupled receptor.

6. The method of claim 5, wherein said G protein-coupled receptor is a constitutively active or hypersensitive mu opioid receptor.

20

7. The method of claim 6, wherein said mu opioid receptor has a single point mutation in transmembrane domain 3.

25

8. The method of claim 7, wherein said single point mutation is an Asn to Ala point mutation at amino acid 150 of SEQ ID NO: 1 or the human equivalent.

9. The method of claim 6, wherein said disorder is back pain.

5

10. The method of claim 1, wherein the expression of said constitutively active, hypersensitive, or nonfunctional receptor is under the control of an inducible, constitutive, or tissue specific promoter.

10

11. The method of claim 1, wherein said nucleic acid encoding said constitutively

active, hypersensitive, or nonfunctional receptor is administered as part of a viral or nonviral vector.

15

12. The method of claim 11, wherein said viral or nonviral vector includes cell specific ligands useful for targeting specific cell-types in a mammal.

13. The method of claim 11, wherein said viral vector is a retroviral, adenoviral, or adeno-associated viral vector.

20

14. The method of claim 1, wherein said hypersensitive receptor is a mu opioid receptor.

15. The method of claim 2, wherein said hypersensitive single transmembrane receptor is an erythropoietin receptor.

25

16. The method of claim 15, wherein said disorder is anemia.

17. The method of claim 5, wherein said G protein-coupled receptor is a
5 nonfunctional CCK-BR receptor.

18. The method of claim 17, wherein said disorder is peptic ulcer disease.

19. The method of claim 5, wherein said G protein-coupled receptor is a
10 constitutively active dopamine receptor.

20. The method of claim 19, wherein said dopamine receptor is a dopamine 1
receptor or a dopamine 2 receptor.

15 21. The method of claim 19, wherein said disorder is Parkinson's disease.

22. A therapeutic composition for treating or preventing a disorder or for
improving the health of a mammal, comprising a nucleic acid encoding a constitutively
active, hypersensitive, or nonfunctional receptor admixed with a pharmaceutically
20 acceptable carrier substance, said nucleic acid being present in said composition in an
amount equivalent to a unit dose suitable for administration to a mammal suffering from
said disorder.

23. A kit for the administration of a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor to a mammal, comprising a container means containing a nucleic acid encoding a constitutively active, hypersensitive, or nonfunctional receptor in a pharmaceutically acceptable carrier.

5

24. The therapeutic composition or kit of claim 22 or 23, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a G protein-coupled receptor.

10

25. The therapeutic composition or kit of claim 22 or 23, wherein said constitutively active or hypersensitive G protein-coupled receptor is a constitutively active or hypersensitive mu opioid receptor.

15

26. The therapeutic composition or kit of claim 25, wherein said mu opioid receptor has a single point mutation in transmembrane domain 3.

27. The therapeutic composition or kit of claim 26, wherein said single point mutation is a Asn to Ala point mutation at amino acid 150 of SEQ ID NO: 1.

20

28. The therapeutic composition or kit of claim 25, wherein said disorder is back pain.

25

29. The therapeutic composition or kit of claim 22 or 23, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a single transmembrane receptor.

30. The therapeutic composition or kit of claim 22 or 23, wherein said constitutively active, hypersensitive, or nonfunctional receptor is a nuclear receptor.

5 31. The therapeutic composition or kit of claim 30, wherein said nuclear receptor is a steroid hormone receptor.

32. The therapeutic composition or kit of claim 22 or 23, wherein the expression of said constitutively active, hypersensitive, or nonfunctional receptor is under the
10 control of an inducible, constitutive, or tissue specific promoter.

33. The therapeutic composition or kit of claim 22 or 23, wherein said nucleic acid encoding said constitutively active, hypersensitive, or nonfunctional receptor is administered as part of a viral or nonviral vector.

15

34. The therapeutic composition or kit of claim 33, wherein said viral or nonviral vector includes cell specific ligands useful for targeting specific cell-types in a mammal.

20 35. The therapeutic composition or kit of claim 30, wherein said viral vector is a retroviral, adenoviral, or adeno-associated viral vector.

36. The therapeutic composition or kit of claim 22 or 23, wherein said single transmembrane receptor is an erythropoietin receptor.

25

37. The therapeutic composition or kit of claim 36, wherein said disorder is anemia.

38. The therapeutic composition or kit of claim 22 or 23, wherein said
5 nonfunctional receptor is a nonfunctional CCK-BR receptor.

39. The therapeutic composition or kit of claim 38, wherein said disorder is peptic ulcer disease.

10 40. The therapeutic composition or kit of claim 22 or 23, wherein said G protein-coupled receptor is a constitutively active dopamine receptor.

41. The method of claim 40, wherein said dopamine receptor is a dopamine 1
receptor or a dopamine 2 receptor.

15

42. The method of claim 40, wherein said disorder is Parkinson's disease.

FIG. 1-1

Constitutively Active Receptors

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP I					
MSHR_mouse	melanocyte-stimulating hormone MSH	TMII	92 VSIVLETTIL K	adenylyl cyclase activity/ HEK293, <i>stably transfected</i>	(Robbins, Nadeau et al. 1993)
CLASS A GROUP II SH1B_human	5-hydroxytryptamine _{1B}	C-terminus of IC3	313 RERKATKTILGI K, R, Q	binding of [³⁵ S]GTP[S] / CHO-K1	(Pauwels, Gouble et al. 1999)
5H2A_human	5-hydroxytryptamine _{2A}	C-terminus of IC3	322 NEQKACKVLGI K	IP production / COS-7	(Egan, Herrick-Davis et al. 1998)
2H2C_rat	5-hydroxytryptamine _{2C}	C-terminus of IC3	312 NEDDASKVLGI L	PI hydrolysis / COS-7	(Herrick-Davis, Egan et al. 1997)

FIG. 1-2

CLASS A GROUP II						
A1AB_human	α_{1B} -adrenergic alpha 1B-AR	TMDI junction between TMDIII and IC2	63 FAIVGNILVIL A 142 CAISIDRYIGV A	IP / COS-7	(Scheer, Fanelli et al. 1997)	
A1AB_human	α_{1B} -adrenergic alpha 1B-AR	junction between TMDIII and IC2	143 CAISIDRYIGV K	IP / COS-7	(Scheer, Costa et al. 2000)	
A1AB_human	α_{1B} -adrenergic	TMDII carboxyl end of IC3 TMV	128 AVDVLCCTASI F 293 REKKA ~~A~~ KTGLI E 204 EPPFYALFSSLG V	IP / COS-1 IP arachidonic acid release IP / COS-1	(Perez, Hwa et al. 1996) (Hwa, Gaivin et al. 1997)	
A1AB_human	α_{1B} -adrenergic	C-terminal IC3	293 SREKKA ~~A~~ KT X=19 different substitutions	PI / COS-7	(Kjelsberg, Cotecchia et al. 1992)	
A1AB_human	α_{1B} -adrenergic	C-terminus IC3	288 293 KFSREKKA ~~A~~ KTGLI K H L	PI hydrolysis / rat fibroblast	(Allen, Lefkowitz et al. 1991)	
A2AA_human	α_2C10 -adrenergic alpha-2AAR	C-terminal IC3 loop	373 (348?) EKRF ~~T~~ TFVLAV X=F, A, C, E, K	adenylyl cyclase inhibition / HEK293	(Ren, Kurose et al. 1993)	
ACM1_human	muscarinic Hm1 muscarinic acetylcholine M1	C-terminal IC3 loop junction	360 SLVKEKKA ~~A~~ RTLS A	PI / HEK(U293)	(Högger, Shockley et al. 1995)	
ACM2-human	muscarinic acetylcholine M2	junction of IC3 and TMVI	390 KKVTRTIL ~~1~~ A 1-4 A inserted	IP production, inhibition of cAMP production / COS-7	(Liu; Blin et al. 1996)	

FIG. 1-3

CLASS A GROUP II							
ACM3_rat	m3 muscarinic (rat)	TMVI		507 TWTPYNIIMVLVNT S	IP / COS-7	(Blüml, Mutschler et al. 1994)	
ACM5_human	muscarinic acetylcholine M3 m5 muscarinic	N-terminus to TMII TMVI		chimera composed of m2 1-69 m5 77-445 m2 391-466	β-gal / NIH 3T3	(Burstein, Spalding et al. 1996)	
ACM5_human	m5 muscarinic muscarinic acetylcholine M5	TMVI		451 459 465 AII ~~L~~ A EII ~~T~~ W TPYNI MVLVST M L H C V S F T	β-gal; radioligand binding / NIH-3T3	(Spalding, Burstein et al. 1998)	
ACM5_human	m5 muscarinic muscarinic acetylcholine M5	junction of TMVI and EC3		465 YNIMVLVSTFCDKCV X=V,F,R,K,+more	β-gal; radioligand binding / NIH-3T3	(Spalding, Burstein et al. 1997)	
B1AR_human	β ₁ -adrenergic	C-terminus		389 RKAFQGLLCCA R	adenylyl cyclase; agonist binding / CHW	(Mason, Moore et al. 1999)	
B2AR_human	β ₂ -adrenergic beta-2AR	C-terminal IC3 loop		266 272 FCLKEHKALKTLGI SR K A	adenylyl cyclase activation; agonist binding affinity / COS-7 or CHO	(Samama, Cotecchia et al. 1993); (Lefkowitz, Cotecchia et al. 1993)	
DADR_human	dopamine D1A	carboxyl terminal IC3		264 SFKMSEKRETKVLKT I K 288 from D1B receptor APDTSIKKETKVLKT	adenylyl cyclase; cAMP accumulation / HEK293	(Charpentier, Jarvie et al. 1996)	
DADR_human	dopamine D1	TMVI		286 FVCCWLPFFIL A	cAMP accumulation / COS-7	(Cho, Taylor et al. 1996)	
HH2R_rat	histamine H ₂	IC2		115 FMISLDRYCAV N,A	cAMP production / HEK-293	(Alewijne, Timmerman et al. 2000)	

FIG. 1-4

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP III					
OPSD_human	opsin	TMII	90 FMVLGGFTSTLY D	transducin; phosphorylation by rhodopsin kinase / COS	(Rim and Oprian 1995)
	rhodopsin	TMIII	113 GCNLEGGFFAT Q		
		TMVII	292 296 MTIPAFFAKSAAY E G, E, M 292 Ala neutral a.a converted to carboxylate and competes with 113Glu for salt bridge with 296Lys		
OPSD_human	opsin rhodopsin	TMIII	134 VVLAIERYVVV I, Q, S	transducin; radioligand binding / COS	(Acharya and Karnik 1996)
OPSD_human	opsin rhodopsin	TM6	257 RMVIMVIAFL Y, N	transducin, GTP-γS uptake / COS	(Han, Smith et al. 1998)
		plus TM3	plus G113Q		
OPSD_human	opsin rhodopsin	TMVII	296 PAFFAKSAAY G X=E,M natural mutants + 10 different a.a. substitutions disrupts critical salt bridge between 296Lys(TMVII) and 113Glu(TMIII)	transducin; radioligand binding / COS	(Govardhan and Oprian 1994); (Cohen, Yang et al. 1993)
		IC2	134 VVLAIERYVVV Q		

5/31

FIG. 1-5

TRFR_mouse	thyrotropin-releasing hormone TRH-R	carboxyl tail	335 FRKLQNCCKQK STOP	⁴⁵ Ca ²⁺ efflux, [Ca ²⁺] / Xenopus oocytes; IP formation / AIT20, <i>stably transfected</i>	(Matus-Leibovitch, Nussenzveig et al. 1995)
------------	--	---------------	----------------------------	--	--

FIG. 1-6

6/31

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP IV					
BRB2_human	bradykinin B ₂ B2 bradykinin BK-2	TMIII TMVI	113 AIIISMNLYSSI A 256 LLFIICWLPFQI F	IP production / COS-7	(Marie, Koch et al. 1999)

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS A GROUP V					
AG2R_rat	AT _{1A} Type-1A angiotensin II	TMIII	111 ASVSFNLYASV A disrupts ¹¹¹ Asn(TMIII) - ²⁹² Tyr(TMVII) interaction	phospholipase C; IP production / COS-7	(Grobowski, Maigret et al. 1997)
AG2R_rat	AT _{1A}	C-terminus of TM7	305 LFYGF ^Q LGKKFK	IP production / HEK- 293; intracellular Ca ²⁺ mobilization / CHO	(Parnot, Bardin et al. 2000)
FMLR_human	Type-1A angiotensin II formylmethionylleucylphenylal anine (fMLPR)	IC1 other multiple mutations	51 LVIVAGFERMTHVTITISYLNKAVA LVVWVTAFEA ^Q KRTINAIWFLNLAVA (K above conflicts with SWISS-PROT database)	PI production; phospholipase C stimulation / COS-7	(Amatruda, Dragas- Graonic et al. 1995)
IL8B_human	interleukin-8 receptor B CXCR-2 chemokine	IC2	138 ACISVDRYLAI ^V HH	IP production; Ca ²⁺ mobilization and actin polymerization / NIH 3T3	(Burger, Burger et al. 1999)
LSHR_human	luteinizing hormone (LH)	IC3	564 MATNKD ^G TKIAKK	cAMP production / HEK293	(Kudo, Osuga et al. 1996)
LSHR_human	luteinizing hormone (LH)	TMVI	578 ILIFTD ^G FTCMA	cAMP production / COS-7	(Shenker, Laue et al. 1993)
LSHR_human	luteinizing hormone (LH)	TM6	571 577 KIAKKMAILIFTD ^I FTCM	cAMP production / COS-7	(Kosugi, Van Dop et al. 1995)
LSHR_rat	luteinizing hormone / human chorionic gonadotropin (LH/hCG)	TMVI	556 ILIFTD ^G FTCMA	cAMP production / HEK 293T	(Bradbury, Kawate et al. 1997; Bradbury and Menon 1999)
OPRD_mouse	delta opiod receptor	TM3	128 KVLSD ^{A,K,H} YNNWF	adenylyl cyclase inhibition / COS-7	(Cavalli, Babey et al. 1999)
OXYR_human	oxytocin	IC2	137 LMSLD ^A RCLAIC	IP production / COS-7	(Fanelli, Barbier et al. 1999)

FIG. 1-8

PAFR_human	platelet-activating factor (PAF)	C-terminus of IC3	231 EVKRRALWMVCTVLAV R	IP production / COS-7	(Parent, Le Gouill et al. 1996)
PAFR_human	platelet-activating factor (PAF)	TMIII	100 CLFFINTYCSV A	arachnidonate release, IP production, adenylyl cyclase inhibition / CHO	(Ishii, Izumi et al. 1997)
PE23_human	prostaglandin E ₂ , EP3III EP3IV	C-terminal tail	360 FCQEEFWGN FCQMRKRRLREQEEFWGN ↑truncated	inhibition of adenylyl cyclase / CHO-K1	(Jin, Mao et al. 1997)
PE23_mouse	prostaglandin E ₂ , EP3	carboxyl-terminal tail	336 KILLRKFCQIRDHT (3α) MMNHL (3β) ↑truncated	inhibition of adenylate cyclase / CHO, <i>stably expressed</i>	(Hasegawa, Negishi et al. 1996)
THR_human	thrombin	EC2 loop	259 268 CHDVLTLLLEGYAYY DLKD KDF I	⁴⁵ Ca ²⁺ efflux, PI hydrolysis, reporter gene induction / COS-7	(Nanevicz, Wang et al. 1996)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	EC1 EC2	486 YYNHAIDWQTG F, M 568 YAKVSI ~~C~~ LPMD T	inositol phosphate-- diacylglycerol cascade / COS-7	(Parma, Van Sande et al. 1995)
TSHR_human	thyrotropin (TSHR) thyroid stimulating hormone	TMIII TMVII	509 ASELSVYTLTV A 672 YPLNSCANPFL Y	adenylyl cyclase activation / COS-7	(Duprez, Parma et al. 1994)
TSHR_human	thyrotropin (TSHR)	TMV	597 VAFVIVCCCHV L	cAMP formation / COS-7 cells	(Esapa, Duprez et al. 1999)
TSHR_human	thyroid stimulating hormone thyrotropin (TSHR)	TMVII	677 CANPFLYAIFT V	cAMP formation / CHO cells	(Russo, Wong et al. 1999)
TSHR_human	thyroid stimulating hormone thyrotropin (TSHR)	IC3	613 621 VRNPQYNPGDKDTKI ~~AK~~ deletion	cAMP formation / COS-7	(Wonerow, Schoneberg et al. 1998)

9/31

FIG. 1-9

TSHR_human	thyrotropin (TSHR)	IC3 / TMVI	623 632 KDTKIAKRM ~~A~~ VLIF ~~T~~ DFICM V I	cAMP activation / COS-7	(Paschke, Tonacchera et al. 1994)
V2R_human	thyroid stimulating hormone vasopressin V2	IC2	136 L ~~A~~ MTLDRHRAI A	cAMP formation / COS-7	(Morin, Cotte et al. 1998)

10/31

FIG. 1-10

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS B GROUP I					
CALR_human	human calcitonin hCTR-1 hCTR-2	wild type (native) protein		adenylyl cyclase cAMP production / COS-1	(Cohen, Thaw et al. 1997)
CLASS B GROUP II					
PTRR_human	parathyroid hormone PTH / PTH-related peptide	junction of IC1 and TMII junction of IC3 and TMVI	223 TRNYIHMHLFL R, K 410 KLLKSTLVLMPC, others	cAMP accumulation / COS-7	(Schipani, Jensen et al. 1997)
CLASS B GROUP III					
GIPR_human	glucose-dependent insulinotropic peptide (GIP-R)	TMVI	340 VFAPVTEEQAR P	cAMP production / L293	(Tseng and Lin 1997)
GLR_rat	glucagon	junction of IC loop I and TMII IC end of TMVI	178 TRNYIHGNLFA R 352 RLARSTLTLLIP A	cAMP accumulation / COS-7	(Hjorth, Orskov et al. 1998)
VIPR_human	vasoactive intestinal peptide 1 (VIP)	junction of IC loop I and TMII junction of IC loop 3 and TMVI	178 RNYIHMHLFI R requires functional integrity of the N-terminal EC domain 343 LARSTLLIP X= K, P	cAMP production / COS-7 or CHO	(Gaudin, Maoret et al. 1998) (Gaudin, Rouyer-Fessard et al. 1998)

FIG. 1-11

11/31

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS C					
CASR_human	calcium-sensing	N-terminal EC	TL ~~S~~ FSFVAQNKID ~~S~~ LD ~~S~~ LN ~~D~~ EEFCNCSEHI various substitutions, in multiple combinations	IP / tsA	(Jensen, Spalding et al. 2000)

FIG. 1-12

File Name	Receptor	Mutation Site	Sequence	Assay / Cells	Reference
CLASS D					
O74283 RCB2 C. cinereus	pheromone	TM6	229 PLSAYQIYVLGT P	heterologous yeast assay	(Olesnicky, Brown et al. 1999)
STE2_yeast	pheromone α -factor	TM6	258 QSLVPSIIFI LL	<i>lacZ</i> reporter gene	(Konopka, Margarit et al. 1996)
STE2_yeast	pheromone α -factor	double mutations TM5 and TM6	223 MSFVLVVKILLAIR C C 247 251 DSFHILLICQSLL CC CC double mutations double mutations	<i>lacZ</i> reporter gene / yeast	(Dube, DeCostanzo et al. 2000)
STE3_yeast	pheromone α -factor	IC3	194 DVRDILHCTNS Q	β -galactosidase	(Boone, Davis et al. 1993)
STE2_yeast	pheromone α -factor	TM6	253 258 LIMSCQSLVPSIIFI L LP	β -galactosidase	(Sommers, Martin et al. 2000)

FIG. 1-13

Bibliography

- Acharya, S. and S. S. Karnik (1996). "Modulation of GDP release from transducin by the conserved Glu134-Arg135 sequence in rhodopsin." J Biol Chem 271(41): 25406-11.
- Alewijnse, A. E., H. Timmerman, et al. (2000). "The Effect of Mutations in the DRY Motif on the Constitutive Activity and Structural Instability of the Histamine H(2) Receptor." Mol Pharmacol 57(5): 890-898.
- Allen, L. F., R. J. Lefkowitz, et al. (1991). "G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity." Proc Natl Acad Sci U S A 88(24): 11354-8.
- Amatruda, T. T., 3rd, S. Dragas-Graonic, et al. (1995). "Signal transduction by the formyl peptide receptor. Studies using chimeric receptors and site-directed mutagenesis define a novel domain for interaction with G-proteins." J Biol Chem 270(47): 28010-3.
- Hüml, K., E. Mutschler, et al. (1994). "Functional role in ligand binding and receptor activation of an asparagine residue present in the sixth transmembrane domain of all muscarinic acetylcholine receptors." J Biol Chem 269(29): 18870-6.
- Boone, C., N. G. Davis, et al. (1993). "Mutations that alter the third cytoplasmic loop of the alpha-factor receptor lead to a constitutive and hypersensitive phenotype." Proc Natl Acad Sci U S A 90(21): 9921-5.
- Bradbury, F. A., N. Kawate, et al. (1997). "Post-translational processing in the Golgi plays a critical role in the trafficking of the luteinizing hormone/human chorionic gonadotropin receptor to the cell surface." J Biol Chem 272(9): 5921-6.
- Bradbury, F. A. and K. M. Menon (1999). "Evidence that constitutively active luteinizing hormone/human chorionic gonadotropin receptors are rapidly internalized." Biochemistry 38(27): 8703-12.
- Burger, M., J. A. Burger, et al. (1999). "Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor." J Immunol 163(4): 2017-22.
- Burgstein, E. S., T. A. Spalding, et al. (1996). "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains." Biochem Pharmacol 51(4): 539-44.
- Cavalli, A., A. M. Babey, et al. (1999). "Altered adenylyl cyclase responsiveness subsequent to point mutations of Asp 128 in the third transmembrane domain of the delta-opioid receptor." Neuroscience 93(3): 1025-31.
- Charpentier, S., K. R. Jarvie, et al. (1996). "Silencing of the constitutive activity of the dopamine D1B receptor. Reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties." J Biol Chem 271(45): 28071-6.
- Cho, W., L. P. Taylor, et al. (1996). "Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction." Mol Pharmacol 50(5): 1338-45.
- Cohen, D. P., C. N. Thaw, et al. (1997). "Human calcitonin receptors exhibit agonist-independent (constitutive) signaling activity." Endocrinology 138(4): 1400-5.
- Cohen, G. B., T. Yang, et al. (1993). "Constitutive activation of opsin: influence of charge at position 134 and size at position 296." Biochemistry 32(23): 6111-5.
- Dube, P., A. DeCostanzo, et al. (2000). "Interaction between transmembrane domains five and six of the alpha-factor receptor." J Biol Chem 275(34): 26492-9.
- Duprez, L., J. Parma, et al. (1994). "Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism." Nat Genet 7(3): 396-401.
- Egan, C. T., K. Herrick-Davis, et al. (1998). "Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs." J Pharmacol Exp Ther 286(1): 85-90.
- Esapa, C. T., L. Duprez, et al. (1999). "A novel thyrotropin receptor mutation in an infant with severe thyrotoxicosis." Thyroid 9(10): 1005-10.
- Fanelli, F., P. Barbier, et al. (1999). "Activation mechanism of human oxytocin receptor: a combined study of experimental and computer-simulated mutagenesis." Mol Pharmacol 56(1): 214-25.
- Gaudin, P., J. J. Maoret, et al. (1998). "Constitutive activation of the human vasoactive intestinal peptide 1 receptor, a member of the new class II family of G protein-coupled receptors." J Biol Chem 273(9): 4990-6.
- Gaudin, P., C. Rouyer-Fessard, et al. (1998). "Constitutive activation of the human VIP1 receptor." Ann N Y Acad Sci 865: 382-5.

FIG. 1-14

- Govardhan, C. P. and D. D. Oprea (1994). "Active site-directed inactivation of constitutively active mutants of rhodopsin." J Biol Chem 269(9): 6524-7.
- Groblewski, T., B. Maigret, et al. (1997). "Mutation of Asn 111 in the third transmembrane domain of the AT1A angiotensin II receptor induces its constitutive activation." J Biol Chem 272(3): 1822-6.
- Han, M., S. O. Smith, et al. (1998). "Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6." Biochemistry 37(22): 8253-61.
- Hasegawa, H., M. Negishi, et al. (1996). "Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity." J Biol Chem 271(4): 1857-60.
- Herrick-Davis, K., C. Egan, et al. (1997). "Activating mutations of the serotonin 5-HT2C receptor." J Neurochem 69(3): 1138-44.
- Hjorth, S. A., C. Orskov, et al. (1998). "Constitutive activity of glucagon receptor mutants." Mol Endocrinol 12(1): 78-86.
- Högger, P., M. S. Shockley, et al. (1995). "Activating and inactivating mutations in N- and C-terminal i3 loop junctions of muscarinic acetylcholine Hm1 receptors." J Biol Chem 270(13): 7405-10.
- Hwa, J., R. Gaivin, et al. (1997). "Synergism of constitutive activity in alpha 1-adrenergic receptor activation." Biochemistry 36(3): 633-9.
- Ishii, I., T. Izumi, et al. (1997). "Alanine exchanges of polar amino acids in the transmembrane domains of a platelet-activating factor receptor generate both constitutively active and inactive mutants." J Biol Chem 272(12): 7846-54.
- Jensen, A. A., T. A. Spalding, et al. (2000). "Functional importance of the Ala 116-Pro 136 region in the calcium-sensing receptor. CONSTITUTIVE ACTIVITY AND INVERSE AGONISM IN A FAMILY C G-PROTEIN-COUPLED RECEPTOR [In Process Citation]." J Biol Chem 275(38): 29547-55.
- Jin, J., G. F. Mao, et al. (1997). "Constitutive activity of human prostaglandin E receptor EP3 isoforms." British J Pharmacol 121: 317-23.
- Kjelsberg, M. A., S. Cotecchia, et al. (1992). "Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation." J Biol Chem 267(3): 1430-3.
- Konopka, J. B., S. M. Margalit, et al. (1996). "Mutation of Pro-258 in transmembrane domain 6 constitutively activates the G protein-coupled alpha-factor receptor." Proc Natl Acad Sci USA 93(13): 6764-9.
- Kosugi, S., C. Van Dop, et al. (1995). "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty." Hum Mol Genet 4(2): 183-8.
- Kudo, M., Y. Osuga, et al. (1996). "Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop." J Biol Chem 271(37): 22470-8.
- Lefkowitz, R. J., S. Cotecchia, et al. (1993). "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins." Trends Pharmacol Sci 14(8): 303-7.
- Liu, J., N. Blin, et al. (1996). "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis." J Biol Chem 271(11): 6172-8.
- Marie, J., C. Koch, et al. (1999). "Constitutive activation of the human bradykinin B2 receptor induced by mutations in transmembrane helices III and VI." Mol Pharmacol 55(1): 92-101.
- Mason, D. A., J. D. Moore, et al. (1999). "A gain-of-function polymorphism in a G-protein coupling domain of the human beta 1-adrenergic receptor." J Biol Chem 274(18): 12670-4.
- Matus-Leibovitch, N., D. R. Nussenzweig, et al. (1995). "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in Xenopus oocytes and AtT20 cells." J Biol Chem 270(3): 1041-7.
- Morin, D., N. Cotte, et al. (1998). "The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities." FEBS Lett 441(3): 470-5.
- Nanevich, T., L. Wang, et al. (1996). "Thrombin receptor activating mutations. Alteration of an extracellular agonist recognition domain causes constitutive signaling." J Biol Chem 271(2): 702-6.
- Olesnick, N. S., A. J. Brown, et al. (1999). "A constitutively active G-protein-coupled receptor causes mating self-compatibility in the mushroom *Coprinus*." EMBO J 18(10): 2756-63.
- Parent, J. L., C. Le Gouill, et al. (1996). "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor." J Biol Chem 271(14): 7949-55.

14/31

FIG. 1-15

- Pärma, J., J. Van Sande, et al. (1995). "Somatic mutations causing constitutive activity of the thyrotropin receptor are the major cause of hyperfunctioning thyroid adenomas: identification of additional mutations activating both the cyclic adenosine 3',5'-monophosphate and inositol phosphate-Ca²⁺ cascades." Mol Endocrinol 9(6): 725-33.
- Parnot, C., S. Bardin, et al. (2000). "Systematic identification of mutations that constitutively activate the angiotensin II type 1A receptor by screening a randomly mutated cDNA library with an original pharmacological bioassay." Proc Natl Acad Sci U S A 97(13): 7615-20.
- Paschke, R., M. Tonacchera, et al. (1994). "Identification and functional characterization of two new somatic mutations causing constitutive activation of the thyrotropin receptor in hyperfunctioning autonomous adenomas of the thyroid." J Clin Endocrinol Metab 79(6): 1785-9.
- Pauwels, P. J., A. Gouble, et al. (1999). "Activation of constitutive 5-hydroxytryptamine 1B receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G-protein interactions [In Process Citation]." Biochem J 343 Pt 2: 435-42.
- Perez, D. M., J. Hwa, et al. (1996). "Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor." Mol Pharmacol 49(1): 112-22.
- Ren, Q., H. Kurose, et al. (1993). "Constitutively active mutants of the alpha 2-adrenergic receptor [published erratum appears in J Biol Chem 1994 Jan 14;269(2):1566]." J Biol Chem 268(22): 16483-7.
- Kim, J. and D. D. Oprian (1995). "Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin." Biochemistry 34(37): 11938-45.
- Robbins, L. S., J. H. Nadeau, et al. (1993). "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function." Cell 72(6): 827-34.
- Russo, D., M. G. Wong, et al. (1999). "A Val 677 activating mutation of the thyrotropin receptor in a Hurthle cell thyroid carcinoma associated with thyrotoxicosis." Thyroid 9(1): 13-7.
- Samama, P., S. Cotecchia, et al. (1993). "A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model." Journal of Biological Chemistry 268(7): 4625-36.
- Scheer, A., T. Costa, et al. (2000). "Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation." Mol Pharmacol 57(2): 219-31.
- Scheer, A., F. Fanelli, et al. (1997). "The activation process of the alpha 1B-adrenergic receptor: potential role of protonation and hydrophobicity of a highly conserved aspartate." Proc Natl Acad Sci U S A 94(3): 808-13.
- Schipani, E., G. S. Jensen, et al. (1997). "Constitutive activation of the cyclic adenosine 3',5'-monophosphate signaling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia." Mol Endocrinol 11(7): 851-8.
- Shenker, A., L. Laue, et al. (1993). "A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty [see comments]." Nature 365(6447): 652-4.
- Sommers, C. M., N. P. Marín, et al. (2000). "A limited spectrum of mutations causes constitutive activation of the yeast alpha-factor receptor." Biochemistry 39(23): 6898-909.
- Spalding, T. A., E. S. Burstein, et al. (1998). "Identification of a ligand-dependent switch within a muscarinic receptor." J Biol Chem 273(34): 21563-8.
- Spalding, T. A., E. S. Burstein, et al. (1997). "Constitutive activation of the m5 muscarinic receptor by a series of mutations at the extracellular end of transmembrane 6." Biochemistry 36(33): 10109-16.
- Tseng, C. C. and L. Lin (1997). "A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity." Biochem Biophys Res Commun 232(1): 96-100.
- Wonerow, P., T. Schöneberg, et al. (1998). "Deletions in the third intracellular loop of the thyrotropin receptor. A new mechanism for constitutive activation." J Biol Chem 273(14): 7900-5.

15/31

FIG. 2

A Point Mutation Enhances MC-4 Receptor
Constitutive Activity




FIG. 3

Light Emission Induced by the WT CCK-BR
vs. a Constitutively Active Mutant




FIG. 4

A Point Mutation Confers Constitutive Activity
to the Rat μ Opioid Receptor




FIG. 5

Forskolin Stimulated HEK293 Cells Transfected
With pcDNA1 and a CRE-luc Construct




FIG. 6

The Rat μ Opioid Receptor Signals Through G α i





FIG. 7

A Point Mutation Confers Constitutive Activity to the Rat μ Opioid Receptor



Target Residues Within Class I GPCRs




FIG. 8

FIG. 9

TMD III Asn (-14 from DRY) is a Target
for Mutation Induced Constitutive Activity




FIG. 10

The 'DRY' Motif is a Target for Mutation
Induced Constitutive Activity




FIG. 11

A Point Mutation Enhances MC-4 Receptor
Constitutive Activity





FIG. 12

The -13 Position is a Target for Mutation
Induced Constitutive Activity



27/31

FIG. 13

```

ork      1  -----MESPIQIFRGEPTCAPSACLPPNSSAWFPGWAEP..DSNGSAGSEDAQ
orkr     1  -----MESPIQIFRGEPTCAPSACLPPNSSSWFPPNWAES..DSNGSVGSEDOO
orm      1  MDSSAAPTNASNCTDAIAYSSCSFAPSFGSWV..NLSHLDGNLSOPCGPNRTDLCGRDSL
ormr     1  MDSSTGPGNTSDCSDPIAQASCSPA..PGSWL..NLSHVDGNQSDPCGLNRTGLCGNDL
ord      1  -----MEPAPSAGAEL..Q.PPLFANASDAYPSACPSAGANASG
AT1a     1  -----MALNSSAEDGIKRIQ
BK-2     1  -----MFSPWKISMFLSVREDSVPTTASFSADMLNVTLQGPTLNG.TFAQ

```

```

ork      49  LEPAEISPAI..PVITITAYSNVVFVGLMGNSLVMEVITRYTKMKTATNIYIFNLALADA
orkr     49  LEPAEISPAI..PVITITAYSNVVFVGLMGNSLVMEVITRYTKMKTATNIYIFNLALADA
orm      59  CPPTGS.PSMITAITIMALYSTVCVGLFGNFLVMYVITRYTKMKTATNIYIFNLALADA
ormr     57  CPQTGS.PSMVTAITIMALYSTVCVGLFGNFLVMYVITRYTKMKTATNIYIFNLALADA
ord      37  PPGARSASSLALAIITAYSAVCAVGLFGNVLVMEGITRYTKMKTATNIYIFNLALADA
AT1a     16  DDCPRAGRHSYIFVMIPTLYSIEFVVGIFGNLSLVVIVIFYMKIKKTIVASVFLNLALADL
BK-2     45  SKCPQVEWLGLWLNTHQPPFLWIFVLEATLENIFVLSVFCLHKSSCTVAEIVLGNLAAADL

```

```

ork      107  LVITITMPFQSTVYLMN..SWPFGDVLCKIVISIDYNNMFTSIFTLTMSVDRYIAVCHPVK
orkr     107  LVITITMPFQSAVYLMN..SWPFGDVLCKIVISIDYNNMFTSIFTLTMSVDRYIAVCHPVK
orm      118  LATSTLPFQSNVYLMG..HWPFGLTLCKIVISIDYNNMFTSIFTLTCTMSVDRYIAVCHPVK
ormr     116  LATSTLPFQSNVYLMG..HWPFGLTLCKIVISIDYNNMFTSIFTLTCTMSVDRYIAVCHPVK
ord      97  LATSTLPFQSAKYLME..HWPFGLTLCKIVISIDYNNMFTSIFTLTMSVDRYIAVCHPVK
AT1a     76  CFLLTLPWAVYTAMEYRWPFGNHLCKIASASVTENIYASVELLTCTMSVDRYIAVCHPVK
BK-2     105  ILACGLPFWAITISNNFDWLEGETLCRVNAIISMNLYSSICFLMLVSTDRYIAVCHPVK

```

-14 from DRY

*

```

ork      166  ALDERTPLKAKIINICIWELSSVCHSAVVEGTRVR..EDVDVIECSLOFPDDDYSWWD
orkr     166  ALDERTPLKAKIINICIWELSSVCHSAVVEGTRVR..EDVDVIECSLOFPDDDEYSWWD
orm      177  ALDERTPRNAKIINVCNWELSSAIGLPVMEVATTKYR..Q..GSIDCHLTFSHPTW.YWE
ormr     175  ALDERTPRNAKIINVCNWELSSAIGLPVMEVATTKYR..Q..GSIDCHLTFSHPTW.YWE
ord      156  ALDERTPAKAKIINICIWELSSVCHSAVVEGTRVR..D..GAVVCMLOFPSPSW.MWD
AT1a     136  SRLRRIMLVAKYTCIIITWIMAGLASIPAVIHRNV..YFIENTNITVCAFHYESRN.STLP
BK-2     165  MGRMRGVRWAKIYSIVLWGCALLLSSPMVEFRTMKREYSDEGHNVTA CVISYPS...LIWE

```

```

ork      224  IFMKICVFIFAFVTPVLIITVCYGLMILRLKSVRLSGSREKDRNLRRITRMVLVVAVF
orkr     224  IFMKICVFIFAFVTPVLIITVCYGLMILRLKSVRLSGSREKDRNLRRITRMVLVVAVF
orm      232  NLEKICVFIFAFVTPVLIITVCYGLMILRLKSVRLSGSREKDRNLRRITRMVLVVAVF
ormr     230  NLEKICVFIFAFVTPVLIITVCYGLMILRLKSVRLSGSREKDRNLRRITRMVLVVAVF
ord      211  TVTKICVFIFAFVTPVLIITVCYGLMILRLKSVRLSGSREKDRSLRRITRMVLVVAVF
AT1a     193  IGLGLTKNILEFLEPFLIILTSYTLWALKKAYEIQKNKPRND...IFRIIMAVLLEF
BK-2     222  VFTNMLLNIVGFLRP.LSVITFCTIOMOVLRNEMOKFKEIQTE.RRATVVLVVLLEF

```

```

ork      284  VVCWTPIHIFILVEALGS.T....SHSTAALSSSYFCIALGYTNSSLNPVLYAFLDENF
orkr     284  VVCWTPIHIFILVEALGS.T....SHSTAALSSSYFCIALGYTNSSLNPVLYAFLDENF
orm      292  IVCWTPIHIFVLIKALVTIP.....ETTFQTVSWHFCIALGYTNSSLNPVLYAFLDENF
ormr     290  IVCWTPIHIFVLIKALVTIP.....ETTFQTVSWHFCIALGYTNSSLNPVLYAFLDENF
ord      271  VVCWAPIHIFVIVWTLVDID.....RRDPLVVAALHLCLALGYANSSLNPVLYAFLDENF
AT1a     250  FFSWVPHQIFTFLDVLLQLGVHDKISDIDVTAMPITICLAYFNNCLNPLFYGLGKKF
BK-2     280  IVCWLPFQISTFELTLHRLGILSSCODERIIDVITQIASFMAYSNSCLNPLVYVIVGKRE

```

```

ork      338  KRCFRDFCFPLKMRMEROSTSRMR.NTVOD.PAYLRDHDGMNKPV-----
orkr     338  KRCFRDFCFPIKMRMEROSTSRMR.NTVOD.PASMRDVGGMNKPV-----
orm      346  KRCFREFCIPTSSNTEQONSTRIRONT.RDHPSTANTVDRTNHQLENLEAETAPLP
ormr     344  KRCFREFCIPTSSNTEQONSTRIRONT.REHPSTANTVDRTNHQLENLEAETAPLP
ord      326  KRCFRQLCRKPCGRPDPSFSRAREATARERTACTPSDGPGGGAAA-----
AT1a     310  KKYELQLLKYIPPAKSHS...SLSTKM..STLSYRPSDNMSSSAKKPASCFEVE-
BK-2     340  RKKSWEVYQGVCKGGRSEPIQOMENSM..GTL..RTSISVEROHKLQDWAGSRQ

```

SUBSTITUTE SHEET (RULE 26)

FIG. 14

28/31

mORmouse	1	MDSSAGPGNISDCSDPLA.PASCSPA..PGSWINLSHVDCNOSDPCGPNRTGLGGSHSLC
mORrat	1	MDSSAGPGNISDCSDPLA.QASCSPA..PGSWINLSHVDCNOSDPCGPNRTGLGGNDSLC
mORbovin	1	MDSCAVPTNASNCIDPFTHPSSCSPAPSPSSWVNFESHLEGNLSGPCPNRTGLGGSDRLC
mORhuman	1	MDSSAAPTNASNCIDALAY.SSCSPAPSPGSWVNLSHLDGNLSGPCPNRTGLGGSDSLC
mORpig	1	MDSSADPRNASNCIDPFSPSSMCSPVPSPSWVNFESHLEGNLSGPCPNRTGLGGSDSLC
mORws	1	MEIS...GNISDFLYPLS.....NPVMS.....NSSVLCRNFSNSTSFLNMNGSSRDSTD
ATla	1	-----MALNSSAEDGKRIQDDC
BK-2	1	-----MFSFWKISMFLSVREDSVPTTASFADMLNVTLOGLNG.TFAQSKC
mORmouse	58	PQTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORrat	58	PQTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORbovin	61	PSAGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORhuman	60	PPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORpig	61	PPTGSPSMVTAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
mORws	48	EODKIP.VITAITITITLYSIVCVVGLVGNFLVMYVIVRYTKMKTATNIYIFNLALADALA
ATla	19	PKACRHSYIFVM.IPTLYSIHFVVGIFGNLSLVIVIVYFYMKIKTVASVFLNLALADLCF
BK-2	48	PQVEWLGWINTI.QPPFLWVLFVLATLENI FVLSVFCLHKSSCTVAEIVLGNLAAADLIL
mORmouse	118	TSTLPFQSVNYLMG.TWPFGNILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORrat	118	TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORbovin	121	TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORhuman	120	TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORpig	121	TSTLPFQSVNYLMG.TWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
mORws	107	TSTLPFQSVNYLMG.TWPFCDVCKIVISIDYYNMFTSIFTLCTMSVDRYIAVCHPVKAL
ATla	78	LLTLPLWAVYTAMEYRWPFGNHILCKIASASVTENYVASVFLTCFSDRYIAVHPMKSR
BK-2	107	ACGLPEWATISNNFDLFCETLCFVNATISMNYSICFLMLVSDRYIAVKTMSMG
mORmouse	177	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATTKYRO.....GSIDCTLTFSHPTWYWE
mORrat	177	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATTKYRO.....GSIDCTLTFSHPTWYWE
mORbovin	180	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATTKYRO.....GSIDCTLTFSHPTWYWE
mORhuman	179	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATTKYRO.....GSIDCTLTFSHPTWYWE
mORpig	180	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATTKYRN.....GSIDCALTFSHPTWYWE
mORws	166	DFRTPRNAKIMVNCNWILSSAIGLPVMFMATSTIENQNSPLOVSNFDCTLLFPHPPWYWE
ATla	138	LRRTMLVAKVTCIIWLMAGLASLPVVIHRNV....YFIENTNITVCAFHYESRNSTLP
BK-2	167	RMRGVRWAKLYSLVINGCILLSSPMLVFRIMK...EYSDEGHNVTAQVLSYPS..LIWE
mORmouse	230	NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORrat	230	NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORbovin	233	NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORhuman	232	NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORpig	233	NLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
mORws	226	TLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVLVVVAVF
ATla	193	IGLGLTKNLGGEFPLIILTSYTLIWKALKKAYEIQKNKPRND...IFRLIMAVLFF
BK-2	222	VFTNMLINVGELIP.LSVITFCTMOIMQVLRNNEQKFKIOTE.RRATVVLVVLILF
mORmouse	290	IVCWTPIHIVYIICALITI.....PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORrat	290	IVCWTPIHIVYIICALITI.....PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORbovin	293	IVCWTPIHIVYIICALITI.....PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORhuman	292	IVCWTPIHIVYIICALITI.....PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORpig	293	IVCWTPIHIVYIICALITI.....PETTFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
mORws	286	IVCWTPIHIVYIICALITI.....PNSLFQTVSWHFCIALGYTNSCLNPVLYAFLDENF
ATla	250	FFSWVPHQLFTFDVLIQGVVHDCIKSIDIVDTAMPITICLAYENNCLNPVLYGFLGKKE
BK-2	280	IVCWLPFOISTFDTLHREGLSSCODERIIDVITQIASFMAYSNSCLNPVLYVIVGKRE
mORmouse	344	KRCFREFC..IPTSSSTIEQONSARIRONTRHPSTANTVDRTNHQLENLEAETAPLE
mORrat	344	KRCFREFC..IPTSSSTIEQONSTRIRONTRHPSTANTVDRTNHQLENLEAETAPLE
mORbovin	347	KRCFREFC..IPTSSSTIEQONSTRIRONTRHPSTANTVDRTNHQLENLEAETAPLE
mORhuman	346	KRCFREFC..IPTSSSTIEQONSTRIRONTRHPSTANTVDRTNHQLENLEAETAPLE
mORpig	347	KRCFREFC..IPTSSSTIEQONSARIRONTRHPSTANTVDRTNHQLENLEAETAPLE
mORws	340	KRCFREFC..VPSPSVLDLONSTRNSNPQCEGSSGHKVDRNNRV-----
ATla	310	KRYFLQLLYIPPAKSHS...SLSTKMSLTSYRPSDNMSSSAKKPASCFEVE----
BK-2	340	RKKSWEVYQGVQKGGCRSEPIQMENSMGTL..RTSISVERQIHKLODWAGSRQ---

29/31





FIG. 16

An Intracellular Point Mutation Results in
Loss of Ligand-Induced Function



31/31

FIG. 17

